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ABSTRACT 
 
The experiments in this thesis tested in vitro and in vivo the proposal that zinc-
deficient superoxide dismutase, resulting from mutations or oxidative damage to the 
enzyme, gains ascorbate oxidase activity that contributes to the pathology of 
amyotrophic lateral sclerosis (ALS). They also tested whether flavonoids can help 
protect against this activity. 
The in vitro experiments showed that zinc-extracted Cu/Zn-SOD (Cu-SOD) as 
well as SOD treated with H2O2 or H2O2 plus ascorbate accelerated ascorbate oxidation 
100 to 300 %, while native SOD had no effect. With Cu-SOD, the activity was 
unaffected by EDTA, EGTA, or catalase, showing that the catalytic copper was firmly 
bound and that the H2O2 product of SOD activity was not responsible. Catechin and uric 
acid slowed ascorbate oxidation by Cu-SOD by 72% and 67%, respectively. 
The in vivo study investigated tissue levels of ascorbate and biomarkers of 
oxidative stress in a transgenic mice bearing a mutation in Cu/Zn-SOD as a model of 
familial ALS (FALS mice), and the effects of dietary ascorbate and quercetin. In FALS 
mice on control modified AIN93G diet for 10 weeks compared to the wild-type, liver 
thiobarbituric acid reactive substances (TBARS) were 47% higher and liver oxidized 
vitamin C was 2800% higher. These results support, in liver, that mutant SOD acquired 
ascorbate oxidase activity and increased oxidative stress. The only difference in other 
tissues was a 136% increase in GSH/GSSG ratio in thigh muscle of FALS mice. 
In dietary treatments of FALS mice, spinal cord TBARS was 93 % higher with 
ascorbate-supplemented diet compared to control diet, suggesting that dietary ascorbate 
increased oxidative stress. Also in spinal cord, oxidized-vitamin C was 250% higher in 
ascorbate + quercetin-fed FALS mice, which suggests there is no protection by quercetin 
against ascorbate oxidation. In brain, protein thiols were 56% and 58% lower in 
quercetin-fed and ascorbate + quercetin-fed FALS mice, suggesting that quercetin 
worsened oxidative damage. In liver, quercetin feeding produced a 40% decrease in 
vitamin C, total vitamin C and oxidized-vitamin C, perhaps by down-regulating 
ascorbate biosynthesis.  
 ii
Overall the results support a gain of ascorbate oxidase activity of mutant SOD in 
ALS, but do not support protection by dietary treatment with ascorbate or quercetin. 
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1. LITERATURE REVIEW 
 
I. BACKGROUND AND RATIONALE 
 
1. Epidemiology of Amyotrophic Lateral Sclerosis (ALS) (Charcot’s disease, Lou 
Gehrig’s disease) 
 
Amyotrophic Lateral Sclerosis (ALS) is one of the most serious 
neurodegenerative diseases. The disease is characterized by the loss of  upper motor 
neurons in the cerebral cortex and lower motor neurons in the brain stem and spinal cord 
(Julien JP, 2001). The loss of motor neurons leads to atrophy and degeneration of the 
skeletal muscles that are under the control of these motor neurons. The disease finally 
leads to paralysis of the respiratory muscles and death usually within 3-5 years after the 
clinical onset (Julien JP, 2001). The incidence of the disease all over the world ranges 
from 0.86 to 2.4 per 100,000 per year (McGuire and Nelson, 2006), and it increases with 
age. It often occurs between 40-70 years old, but it can occur in younger and older ages 
(Cwik, V.A., 2001). The prevalence of ALS is about 6 per 100,000 per year. In Canada, 
approximately 2,200 people currently have ALS (http://www.als.ca/als_manuals.aspx).  
Three major forms of ALS have been identified: 1) sporadic ALS, 2) familial or 
hereditary ALS, and 3) the Western Pacific (Mariana Islands) form. The latter was 
identified among the Chamorro people of Guam (Armon C, 1994), and it was described 
pathologically as a complex of Parkinson’s disease (PD) and Alzheimer’s disease. It was 
referred to as ALS Parkinsonium-dementia complex (ASL/PDC) (McGuire and Nelson, 
2006).  
    The Western Pacific form of ALS was discovered in the early 1950s, with 
incidence rates ranging from 50-100 per 100,000 per year.  The male to female ratio was 
2:1 and the average age at diagnosis was 44 years. ALS/PDC was identified in three 
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different areas (McGuire and Nelson, 2006): in Guam (Marianna Islands), the Kii 
Peninsula of Japan, and Irian Jaya (Western New Guinea). The cause of ALS/PDC in 
these areas remains unclear. The spouses of many patients were also affected which does 
not support the hereditary cause of ALS/PDC. There are two hypotheses on the 
pathogenesis of ALS/PSC : mineral deficiency, especially calcium and magnesium in 
soil and drinking water, and poisoning through ingestion of the cycad seed (McGuire 
and Nelson, 2006). The involvement of an environmental agent or toxicant as a cause for 
ALS/PDC needs further investigation. 
The majority of the ALS cases (90%) are sporadic, while only about 10% are 
familial cases (Julien JP, 2001). The incidence of sporadic ALS is 20-60% higher in men 
than in women (McGuire and Nelson, 2006). Of familial cases, 20% are due to 
mutations at the SOD1 gene on chromosome 21 (McGuire and Nelson, 2006). Not all 
carriers of SOD1 mutations will develop ALS, suggesting that other unknown factors 
must be contributing to the development of the disease in familial cases.  
 
2. Risk factors for ALS 
 
There are many risk factors that have been cited in the literature for ALS, 
although the only clear risk factors until now are age and sex (Figure 1.1). Although age 
is a risk factor in ALS, with a maximum susceptibility between the ages of 55 and 70 
years old, other environmental or exogenous factors may be implicated in ALS 
development (Kurtzke JF, 1991). As to sex, there is an increased male to female ratio by 
1.5-2 to 1 (Kurtzke JF, 1991). Regarding race, there is a highly significant decrease in 
ALS for nonwhites in the U.S, which suggests protection for blacks; however there are 
no good surveys that either confirm or reject the protection for U.S. blacks (Kurtzke JF, 
1991). 
Physical trauma, whether mechanical, electrical, or surgical, has been identified 
as the strongest and most consistent risk factor in ALS (Kurtzke JF, 1991). The strong 
association between trauma and ALS may explain the increased incidence of sporadic 
ALS in males rather than females as injury is more frequent in men than in women 
(Kurtzke JF, 1991).                         
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Physical activity was suggested as a risk factor in ALS by several mechanisms 
(Longstreth et al., 1991). Physical activity can increase the risk of exposure to a 
neurotoxin by either facilitating its transport to its target or it can increase the 
susceptibility of motor neurons to injury by the neurotoxin. Epidemiological studies 
found an association between vigorous physical activity at work and during leisure time, 
and ALS (Longstreth et al., 1991) 
 
 
 
Figure 1.1 Etiological theories and proposed risk factors in ALS 
Certain lifestyle factors have been linked to ALS such as diet, alcohol 
consumption, exercise, smoking tobacco, and other environmental factors such as 
residence in rural areas and job-related exposure to certain toxins. The role of cigarette 
smoking and alcohol consumption in the etiology of ALS has been investigated. Only 
three studies (Kamel et al., 1999, Nelson et al., 2000b, Weisskopf et al., 2004) have 
found an association with cigarette smoking, and none of the studies has found an 
association between ALS and alcohol consumption. The mechanisms by which cigarette 
Age 
Sex 
Physical trauma Environmental Agents 
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Amyotrophic Lateral Sclerosis 
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smoke could contribute to the risk of ALS were proposed by Nelson et al., 2000b.  
Nelson and colleagues suggested that cigarettes may directly cause toxic injury to motor 
neurons by its chemical constituents, or indirectly by the formation of free radicals 
during the metabolism of the chemical constituents of cigarette smoke. The hypothesis 
that cigarette smoking is associated with ALS needs further investigation.  
There is a positive association between the increased risk of ALS and dietary fat 
intake, especially saturated fat and polyunsaturated fat such as linoleic acid (Nelson et 
al., 2000a). Fat intake (>93g/day compared with <42g/day) was associated with about a 
three-fold increased risk of ALS (Nelson et al., 2000a). The high concentration of 
polyunsaturated fatty acids in brain makes it vulnerable to oxidative damage (Penzes et 
al., 1993). As the dietary intake of polyunsaturated fatty acids affects their levels in 
brain, the increased consumption of polyunsaturated fatty acids could increase the risk of 
lipid peroxidation in brain (Bourre et al., 1993). On the other hand, dietary fiber intake 
(>18g/day compared with <10g/day) was found to decrease the risk of ALS by 70% 
(Nelson et al., 2000a). A mechanism by which dietary fiber could protect against the 
development of ALS is to cause luminal dilution of potential carcinogens (Hillemeier C, 
1995), so it could reduce the absorption of a dietary toxin associated with ALS. Dietary 
fiber also was proven to shorten the transit time in the large intestine (Hillemeier C, 
1995) and thereby could reduce the absorption of a dietary toxin. 
The role of dietary antioxidants in ALS is inconclusive. A recent study 
investigated the relationship between the use of vitamin E, vitamin C, vitamin A, and 
multivitamin supplements and ALS mortality (Ascherio et al., 2005). In this study a 
group of one million people were surveyed and the investigators reported 525 deaths 
from ALS. The subjects were classified into 3 groups: nonusers of vitamin E, C, A, and 
multivitamin supplements, occasional users (less than 15 times per month), and regular 
users (15 times or more per month). It was found that regular use of vitamin E 
supplements for more than 10 years reduced the risk of death from ALS by 62%. On the 
other hand, vitamin C, vitamin A, and the use of multivitamins did not affect the risk of 
ALS. This agrees with the results from animal studies, as in one study it was found that 
dietary supplementation with vitamin E to transgenic mice over-expressing one of the 
mutated SOD1 genes delayed the onset of motor neuron disease (Gurney et al., 1996). 
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However, another study from Washington State university did not find any association 
of antioxidant and vitamin consumption, either in the diet or as a supplement, with the 
risk of ALS (Nelson et al., 2000a).  Further studies need to be done to investigate more 
the role of diet in ALS.                                                                                                                                 
Although there is still no clear evidence that a single environmental agent could 
directly cause ALS, epidemiological studies still suggest that environmental causes are 
important to study to clearly understand their roles in ALS. 
 
3. Clinical motor signs and symptoms of ALS 
 
ALS is a progressive degenerative disease of both upper motor neurons (UMN) 
and lower motor neurons (LMN). There is no specific test to confirm the diagnosis of 
ALS. The diagnosis is mainly dependent on the recognition of the disease signs and 
symptoms (Cwik, V.A., 2006). It is also dependent on the exclusion of other 
neurodegenerative diseases that might have similar signs and symptoms. The early 
symptoms of ALS are usually not clear enough and many people consider them as 
normal signs of aging. They include tripping, dropping things, slurred speech, and 
muscle weakening. Weakness of the respiratory muscles develops slowly over months or 
years (http://www.als.ca/als_manuals.aspx). 
The diagnosis of ALS depends on the presence of both UMN and LMN 
abnormalities. The signs of UMN abnormalities are hard to quantify compared to LMN 
ones, as the UMN lesions in ALS are not responsible for the major disabilities that occur 
in the disease. The signs of UMN abnormalities include muscle stiffness or rigidity, 
emotional lability (decreased ability to control laughing or crying) and increased or 
hyperactive reflexes. The weakness due to UMN loss in ALS is usually masked by the 
weakness due to LMN lesions, and this is why it is hard to quantify clinically (Cwik, 
V.A., 2006). The signs of LMN loss include muscle weakness and atrophy. In early 
stages of ALS, LMN lesions are not disabling; however, the lesions accumulate over 
time and become more disabling.  
 
 
 5
 4. The causes of sporadic ALS 
 
Approximately 90% of ALS cases are sporadic cases (SALS) with no family 
history of ALS (Siddique et al., 1989). There is evidence that suggests that multiple 
genetic and environmental factors may be involved in ALS pathogenesis (Julien JP, 
2001). We still do not know much about the genetic defects that cause or predispose to 
ALS. The only proven cause of ALS is missense mutations in the SOD1 gene. This 
accounts for about 20% of familial ALS cases (Rosen et al., 1993). Mutations in the 
neurofilament NF-H gene have been identified in a small number of sporadic ALS 
patients (~1% of cases) (Cleveland DW, 1999). The data suggest that NF-H mutations 
may represent risk factors for ALS disease (Julien JP, 2001). 
    For the majority of ALS cases, the main cause of sporadic ALS is still unclear. 
Various hypotheses have been suggested such as oxidative damage, excitotoxicity, 
mitochondrial defects and autoimmunity but these could be secondary to the 
neurodegeneration process and not the leading cause of ALS (Julien JP, 2001). 
 
5. Familial ALS and genetic links to ALS  
 
Approximately 10% of cases are familial ALS (FALS). Seven ALS-associated 
genes to date have been identified; however, only three of theses genes have been 
precisely located (http://www.als.ca/als_manuals.aspx). ALS1 gene, which codes for the 
abnormal form of the enzyme copper-zinc superoxide dismutase (SOD1) on 
chromosome 21, causes the most common form of Familial ALS. While mutations in 
SOD1 account for ~20% of familial ALS (Rosen et al., 1993), identifying the remaining 
80% of FALS cases will need further investigation. 
 
5.1 Cu/Zn superoxide dismutase structure and activities 
 
Superoxide dismutases are a group of enzymes that catalyze the conversion of 
the superoxide anion (O2•-) into hydrogen peroxide and oxygen. SODs protect against 
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the toxic effects of O2•- and its derivatives (Siddique et al., 1997). In humans there are 
three types of SOD: cytosolic Cu, Zn superoxide dismutase (SOD1, CuZnSOD), 
mitochondrial Mn superoxide dismutase (SOD2, MnSOD), and extracellular superoxide 
dismutase (SOD3, ECSOD), which is also a CuZn enzyme. No mutations in SOD2 or 
SOD3 have been reported in FALS patients (Parboosingh et al., 1995). 
    SOD1 is present in the cytoplasm of most cells including red blood cells and is 
abundant in neurons (Pardo et al., 1995). Each SOD1 monomer has 153 amino acids and 
a mass of 16 KiloDaltons. Each monomer contains one atom each of Cu and Zn. The 
zinc is very important for pH stability of the reaction and for the rapid dissociation of the 
H2O2 produced, which can inactivate SOD1 (Hand and Rouleau, 2002). Access to the 
active site is limited by size and charge of the molecules. It usually favors small, 
negatively charged molecules such as the superoxide anion O2•- and excludes molecules 
with positive charges or large size (Siddique et al., 1997). The two-step dismutase 
reaction proceeds as follows: 
               O2•- + Enz-Cu ++ + H+ → O2 + Enz-Cu+                                         (1.1)       
    
               O2•- + Enz-Cu+ + H+ → H2O2 + Enz-Cu++                                   (1.2) 
 
The net reaction is: 
               2O2•- + 2H+ → H2O2 + O2                                                                   (1.3) 
 
Besides the dismutase activity, SOD1 has a marginal peroxidase activity 
(Hodgson and Fridovich, 1975). H2O2, which is the product of the dismutase reaction, 
inactivates SOD1. The inactivation of SOD1 by its own H2O2 product and peroxidase 
activity would proceed as follows: 
               H2O2 + Enz-Cu++          O2•- + Enz-Cu+ + 2H+                                                   (1.4)     
                        
               Enz-Cu+ + H2O2           Enz-Cu++ – OH• + OH-                                                (1.5) 
 
               Enz-Cu++ – OH• + ImHis63 → Enz-Cu++ + ImHis63• + H2O          (1.6) 
 
Enz is the enzyme and ImH63 is the imidazole moiety of the histidine residue at position 
63 of the SOD1 polypeptide. In vivo, the peroxidase activity would be significant only 
in the presence of an excess production of H2O2 which may result from increased 
production of O2•- molecules as in oxidative stress conditions (Yim et al., 1993). 
 
 7
 5.2 Cu/Zn SOD1 mutation in FALS 
 
The first ALS-associated gene to be identified was the SOD1 gene, on human 
chromosome 21 (Rosen et al., 1993). SOD1 gene is about 11 kb in size, and the SOD1 
protein consists of 153 highly conserved amino acids with copper and zinc binding sites 
(Deng et al., 1993). Over 100 mutations, predominantly missense, have been found in 68 
of the 153 positions in the protein (Siddique et al., 1996).  For most people with SOD 
mutations, the time of death is typically three to five years after onset of symptoms, 
which is similar to the death in sporadic ALS. Certain SOD mutations, such as A4V and 
A4T, cause a more rapid progression of the disease, with death occurring within a year 
after diagnosis (Beckman and Estevez, 2006). 
The discovery of SOD1 mutations associated with ALS shed light on the 
mechanism by which the mutated enzyme could cause the disease. It was first suggested  
that the disease was caused by loss of the scavenging activity of the mutant SOD1 
enzyme, which leads to accumulation of the harmful superoxide anions (Rosen et al., 
1993). Decreased SOD1 activity in the cerebrospinal fluid (CSF) of ALS patients has 
been reported (Bracco et al., 1991). Another mechanism was that mutant SOD might 
produce excessive hydrogen peroxide, which may be rapidly converted to the more toxic 
hydroxyl radical in the presence of ferrous ions (Imlay et al., 1988). The loss of function 
hypothesis was disproved by measurement of enzymatic activities and by transgenic 
mouse studies. Transgenic mice expressing familial ALS-linked mutant SOD1G93A (i.e., 
glycine substituted to alanine at position 93) or SOD1 G37R developed motor neuron 
disease despite elevation in SOD1 activity levels (Cleveland DW, 1999). In addition, 
SOD1 knockout mice did not develop motor neuron disease (Reaume et al., 1996). 
Therefore, it is proposed that the mutations in SOD1 lead to a gain of new toxic 
properties rather than loss of the scavenging activity of SOD1 (Julien JP, 2001). 
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5.3 The mechanism of SOD1-induced oxidative damage to motor neurons 
 
Although the toxic gain of function of mutant SOD1 has not yet been 
determined, there are various hypotheses of SOD1-mediated toxicity including: copper 
toxicity, improper metal binding, oxidative stress, abnormal protein aggregation, 
disorganization of neurofilaments, glutamate-mediated excitotoxicity, mitochondrial 
dysfunction and apoptosis (Kunst CB, 2004).  
 
5.3.1 The copper-mediated oxidative damage hypothesis 
 
One of the first hypotheses of SOD1-mediated toxicity was copper-mediated 
oxidative damage by the mutant SOD1 enzyme. In this hypothesis it is proposed that the 
misfolding of SOD1 caused by mutations can cause some undesirable substrates such as 
peroxynitrite to reach the catalytic site, hence lead to nitration of tyrosine residues 
(Beckman et al., 1993). Consistent with this hypothesis were findings of increased levels 
of free 3-nitrotyrosine in the spinal cord of human ALS patients (Beal et al., 1997) and 
free but not protein bound 3-nitrotyrosine in mouse models of ALS (Bruijn et al., 1997). 
Another hypothesis was that the mutant SOD1 enzyme can use the produced hydrogen 
peroxide as a substrate to generate toxic hydroxyl radicals that can cause cellular 
damage (Wiedau-Pazos et al., 1996). Elevated hydroxyl radical-like activity in mice 
expressing mutant SOD1 was found (Bogdanov et al., 1998). However there was an 
argument against the peroxidase activity hypothesis after the results of an activity study 
that was done in a mouse model of ALS (Bruijn et al., 1997). In that study they 
generated mutant SOD1G85R mice either in SOD1 knockout mice or in transgenic mice 
overexpressing the wild type SOD1. It was expected that deleting the wild type-SOD1 in 
SOD1G85R mutant mice would increase the levels of superoxide anion or the hydroxyl 
radicals while increasing the normal SOD1 activity would do the opposite. It was found 
that neither the elimination nor the excessive activity of the wild type SOD1 affected the 
disease progression in SOD1G85R mice (Bruijn et al., 1997). This argues against the 
mechanism of disease progression involving superoxide anion or hydroxyl radicals. On 
the other hand there were some studies that tried to investigate the role of copper in the 
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pathogenesis of FALS. It was found in one study that deleting the gene for the copper 
chaperone for SOD (CCS), which is necessary for inserting copper in SOD1 did not 
affect the onset or the progression of the disease in mutant SOD1 mice, although it did 
decrease the copper content of the enzyme (Subramaniam et al., 2002). In another study 
they found that mutation of the four copper binding histidine residues, which results in a 
copper-less enzyme, also caused motor neuron disease in mice (Wang et al., 2003). 
These experiments suggest that the copper-mediated oxidative damage by the mutant 
SOD1 enzymes is not the primary cause of motor neuron degeneration in these models 
of FALS. However these experiments to not discount that increased levels of free (non-
SOD bound) copper may have contributed to the motor neuron disease in these cases. 
 
5.3.2 Improper metal binding hypothesis 
 
Improper metal binding is another proposed hypothesis by which the mutant 
SOD1 enzymes could exert their new toxic function. ALS-related SOD mutants have 
decreased Zn affinity and when they are expressed in vitro, they accumulate in a Zn-
deficient state (Crow et al., 1997). In SOD enzymes, Zn affinity is usually less than 
copper and Zn is held 7000-fold less strongly than copper (Crow et al., 1997). Mutation 
in SOD can weaken the enzyme structure and consequently cause Zn to be lost from the 
active site more easily than copper. The copper in the active site of the zinc-deficient 
SOD1 becomes more accessible, and it is suggested to participate in harmful reactions 
including transferring electrons to oxygen to produce superoxide (Estevez et al., 1999). 
Nitric oxide reacts very rapidly with superoxide to produce peroxynitrite.  
In one experiment they found that the wild type zinc-depleted SOD1 and the 
mutant SOD1 lacking zinc were equally toxic to cultured motorneurons (Estevez et al., 
1999). On the basis of these results, it is proposed that the mutations to the SOD enzyme 
could increase its susceptibility to lose Zn. Thus, wild type SOD can participate in 
sporadic ALS if it becomes Zn deficient (Beckman et al., 2001).  
         The question is what causes SOD to become Zn deficient in motorneurons? It was 
found that neurofilaments, a highly expressed protein in motorneurons, have high 
capacity for binding Zn and even compete with SOD for binding Zn in vitro (Crow et 
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al., 1997). The high concentration of neurofilaments combined with their high capacity 
for binding zinc could explain the tendency of SOD to become Zn deficient and 
consequently kill the motorneurons in vivo. Deletion of the light subunit of 
neurofilament (NF-L) subunit protects motorneurons against mutant SOD in ALS 
transgenic mice (Julien JP, 2001). So any abnormal upregulation of neurofilament 
proteins or other Zn-binding proteins such as metallothionein could result in the 
production of Zn-deficient SOD from even the wild type enzyme and thus could explain 
the genesis of sporadic ALS (Beckman et al., 2001). 
 
5.3.3 Toxic protein aggregates 
 
Another hypothesis to explain the toxicity of mutant SOD1 in FALS was the 
formation of toxic protein aggregates from the misfolded mutant proteins. The presence 
of protein aggregates is considered a pathological mark of the mutant SOD1 mouse 
model of ALS (Dal Canto and Gurney, 1995). Different hypotheses have been proposed 
to explain the toxicity of these aggregates. First it was proposed that mutant SOD1 
aggregates may seize other protein components that are necessary for neuronal function. 
Second, the repetitive misfolding of the SOD1 mutants and their aggregates could result 
in reduced capacity of protein chaperones which catalyze the folding and unfolding of 
proteins inside the cell (Bruening et al., 1999). Third, the SOD1 mutant aggregates 
overwhelm the capacity of the ubiquitin-proteasome to degrade other protein 
components (Johnston et al., 2000).  
It was found that aggregates of mutant SOD1 are found mainly within the 
nervous system of mutant SOD1 transgenic mice (Puttaparthi et al., 2003). In one study 
by Puttaparthi et al. (2003), they showed that proteasome-mediated protein degradation 
represents the major clearance mechanism for SOD1 aggregates in spinal cord. The 
proteasome activity was found to be decreased in spinal cord during aging, and this 
decrease correlates with accumulation and aggregation of mutant SOD1 in vivo 
(Puttaparthi et al., 2003). These observations could explain the selective vulnerability of 
motor neurons to mutant SOD1 with increased age. 
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5.3.4 Mitochondrial defects 
 
There is some evidence that links mutation in SOD1 to mitochondrial 
dysfunction. First SOD1 was considered as a cytoplasmic protein, but recent studies 
have shown that ~1-2% of SOD1 is found in the intermembrane space of mitochondria 
(Mattiazzi et al., 2002). One of the early pathological signs in G93A and G37R SOD1 
transgenic mice is the presence of large membrane-bound vacuoles that came from 
degenerating mitochondria in motor neurons (Dal Canto and Gurney, 1995). Studies 
have shown increasing numbers of degenerating mitochondria within motor neurons 
immediately before the onset of symptoms in G93A transgenic mice (Kong and Xu, 
1998). Damaged mitochondria can produce many toxic effects such as excess production 
of superoxide ion, and release of cytochrome c into the cytoplasm, which activates 
caspase-3, and affects Ca2+ homeostasis. In SOD G93A transgenic mice, there is evidence 
of impaired calcium homeostasis in motor neurons which leads to motor neuron 
degeneration (Siklos et al., 1998).  
 
5.3.5 Glutamate Excitotoxicity 
 
Glutamate is considered the principal excitatory neurotransmitter in the brain. 
The receptor excitation that results from presynaptic glutamate release is usually 
terminated by reuptake of glutamate by specific transporters (Heath and Shaw, 2006). 
Failure of glutamate uptake by these transporters leads to excessive excitation to the 
receptors and neurotoxic effects. Glutamate excitotoxicity leads to calcium and sodium 
influx and activation of some enzymes such as nitric oxide synthase (NOS) (Leigh and 
Meldrum, 1996). This may lead to the formation of NO, which contributes to protein 
nitration and inactivation. For spinal motor neurons, the specific glutamate transporter is 
EAAT2 (excitatory amino acid transporter), and is present in astrocytes. It was found 
that the majority of sporadic ALS cases (~65%) have a decrease in the astroglial 
glutamate transporter EAAT2 in motor cortex and spinal cord (Rothstein et al., 1995). 
This decrease in EAAT2 levels may be due to RNA processing errors which lead to the 
formation of aberrant EAAT2 mRNA species.  
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In patients with familial ALS, mutant SOD1 could catalyze the inactivation of 
EAAT2, as it does in the presence of hydrogen peroxide (Trotti et al., 1999), and lead to 
excitotoxic injury. This process would represent another link between familial and 
sporadic ALS. To date, the only effective approved treatment for ALS is riluzole. It has 
a neuroprotective role by inhibiting glutamate release (Doble A, 1996). Treatment with 
riluzole significantly prolongs the survival by 13-15 days, an improvement of about 11% 
in the animal model of ALS (Gurney et al., 1996). Another potential treatment may be 
the use of carboxyfullerenes. These antioxidants exhibit neuroprotective properties by 
blocking glutamate receptor-mediated excitotoxicity (Dugan et al., 1997) 
 
5.3.6 Neurofilaments 
 
Neurofilaments are considered possible targets of SOD1-induced toxicity. The 
neurofilament proteins, which are composed of heavy (NF-H), medium (NF-M), and 
light (NF-L) subunits have an important role in axonal transport (Rowland and Shneider, 
2001). Aggregation of neurofilaments was found in both sporadic and familial ALS 
patients (Hirano et al., 1984) as well as in SOD1-knockout mice (Rouleau et al., 
1996).The overexpression in mice of any of the three wild type neurofilament subunits 
leads to the formation of perikaryal neurofilament aggregations. But, neurofilament 
aggregations in the cell body of motor neurons do not cause death of motor neurons. For 
example, NF-H protein overexpression caused severe motor dysfunction but did not 
cause motor neuron death even in two-year old mice (Beaulieu et al., 2000). It was 
found that overexpression of the wild type human NF-H, or to a lower extent mouse NF-
H proteins, which causes perikaryal neurofilament inclusions or accumulation of NFs in 
the cell body and not in the axons of motor neurons, extended the longevity of mutant 
SOD1 mice by 65% and 15%, respectively (Kong and Xu, 2000). The most effective 
approach to increase the longevity of mutant SOD1 mice is overexpressing human NF-H 
proteins. The proposed protective mechanism might be that the accumulation of 
perikaryal neurofilament may protect the cell by binding excess Ca2+ or by acting as a 
sink for oxidative damage. 
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5.3.8 Oxidative stress 
 
Oxidative stress occurs when there is imbalance between production of oxidants, 
such as superoxide anion (O2·-), hydroxyl radicals (·OH), and hydrogen peroxide (H2O2), 
and the antioxidant defence mechanism inside the cell (Coyle and Puttfarcken, 1993). 
There are a number of defence mechanisms in the cell to reduce the levels of oxidants: 
SOD, catalase, ascorbic acid (vitamin C), and α-tocopherol (vitamin E). Studies have 
shown that reactive oxygen species (ROS) production is increased in ALS and is 
associated with the disease onset and progression (Said et al., 2000). The high ROS 
levels could cause motor neuron degeneration by either reacting with, and damaging the 
cellular macromolecules inside the cell, or by stimulating the expression of genes that 
are associated with inflammation (Xu and Kong, 2006). The benefit of antioxidants in 
ALS was demonstrated by vitamin E treatment of transgenic SOD1 mutant mice 
(Gurney et al., 1996). Treatment with vitamin E and selenium delays the onset of clinical 
disease in SOD1G93A transgenic mice by 12-15 days (14%), although it did not affect 
disease progression (Gurney et al., 1996).  
 
II. Therapeutic approaches in ALS 
 
Different therapeutic agents have been tried in mutant SOD1 mice and they have 
proved to slow disease progression. Riluzole, an inhibitor of glutamate release, is the 
only drug approved by the Food and Drug Administration for the treatment of ALS. 
Riluzole was found to prolong the survival of SOD G93A mice by 10-15 days, without 
affecting the disease onset (Gurney et al., 1996). Similarly, gabapentine, an inhibitor of 
glutamate biosynthesis, was found to extend the survival in transgenic mice with mutant 
SOD1, but it did not significantly delay the disease onset (Gurney et al., 1996). In 
contrast, vitamin E was found to delay the onset and the progression of the disease 
without extending the survival of the transgenic mice. Despite being beneficial in mice, 
gabapentine plus vitamin E did not show any benefits in patients with ALS (Miller et al., 
2001). 
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Other therapeutic targets have been tested in mice. The overexpression of Bcl-2 
was found to extend the survival of SOD1G93A mice by 5-6 weeks (Kostic et al., 1997). 
The highest reported effect on the survival of mutant SOD1 mice (~5 months) was 
obtained by overexpressing a human NF-H transgene (Couillard-Despres et al., 1998). 
Another approach in treating ALS is using zinc supplementation. If zinc-deficient SOD 
could cause motor neuron death in ALS, a zinc-deficient diet fed to transgenic animals 
should accelerate the disease progression and zinc supplements might be protective. 
Disagreeing with this hypothesis, it was found that the high dose of zinc that was added 
to drinking water accelerated the death of ALS-SOD transgenic mice (Groeneveld et al., 
2003).The zinc dosages were 75 and 375 mg/kg/day of zinc, which were 15 to 75 times 
greater than current recommendations for rodents (Reeves et al., 1993b). Excess zinc 
was found to block copper absorption and it is used to treat copper overload in Wilson’s 
disease. On the other hand, copper is important for ceruloplasmin which inserts iron into 
heme and its deficiency causes fatal anaemia (Fox PL, 2003). Another study found that 
using moderate dose of zinc (12 mg/kg/day) extended the mice survival by 11 days 
compared to the zinc-deficient group (Ermilova et al., 2005). Increasing the dose to 
18mg/kg/day accelerated the mice death, which can be prevented by the addition of a 
low dosage of copper to the drinking water. These results indicate that zinc 
supplementation could be used to treat ALS in transgenic mice with moderate dosage 
and without affecting the balance between copper and zinc inside the body. 
 
III. The role of ascorbic acid as antioxidant in ALS 
 
Ascorbate is an important antioxidant, enzyme co-factor and neuromodulator in 
the brain (Rice ME, 2000). Ascorbate enters the CNS by active transport and it diffuses 
from the cerebrospinal fluid (CSF) to the brain extracellular fluid (ECF) (Schenk et al., 
1982). From the ECF, ascorbate is transferred to brain cells, where its concentration is 
increased up to 20-fold. The brain, spinal cord and adrenal glands have the highest 
ascorbate concentrations of all the tissues in the body (Rice ME, 2000).  
Both SOD and ascorbate eliminate O2•-, producing hydrogen peroxide as a product. The 
high levels of ascorbate in neurons enable it to compete with Cu/Zn-SOD for O2•-
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elimination (Rice and Russo-Menna, 1998). In this way, intracellular ascorbate levels 
may compete against the excessive formation of toxic product generated by the mutant 
SOD. A decrease in cytoplasmic ascorbate levels would increase O2•- metabolism by the 
mutant SOD, and consequently allow more toxic product to form (Kok AB, 1997). 
Ascorbate could play both a direct and an indirect antioxidant role in ALS. First, 
ascorbate can directly reduce the superoxide radicals and hence prevent their direct 
damage to the cell, and their indirect damage through superoxide reactions with H2O2 to 
form hydroxyl radicals or with nitric oxide to form peroxynitrite anions (Kok AB, 1997). 
In a second indirect mechanism, ascorbate can restore oxidized vitamin E, which has 
been reported to delay ALS onset in transgenic mice (Dal Canto and Gurney, 1995). It 
has been reported that long-term users of vitamin E supplements had less than half the 
risk of dying from ALS than nonusers, suggesting that vitamin E supplementation may 
have a role in ALS prevention (Ascherio et al., 2005). 
A correlation has been found between physiological ascorbate levels and the 
characteristics of ALS with respect to age and gender. First, there is an age-dependent 
decrease in ascorbate levels in both serum and tissue levels, which is consistent with the 
delayed onset of ALS (Kok AB, 1997). Second, men show lower plasma ascorbate 
levels, and animal studies have shown increased demand for ascorbate in males under 
injury conditions. Males clearly develop the disease earlier than females (Rosen AD, 
1978). 
The efficacy of combined treatment with a copper chelator triethylenetetramine 
dihydrochloride (trientine) and ascorbate on the disease development in mutant SOD1 
transgenic mice has been demonstrated (Nagano et al., 1999). In this study, a high dose 
of trientine in the distilled water (0.2% w/v) and ascorbate mixed in the standard AIN-
93G diet at the concentration of  0.8% w/w was initiated before the onset of the disease 
at 45 days of age.  This combined treatment extended the survival of the transgenic mice 
by 11 % and maintained the motor function of the mice longer than the diseased control. 
They determined the onset of the neurological signs by postural change of one limb and 
the end point by the total paralysis of hind limbs when the mouse was lifted by the tail. 
The onset of neurological symptoms in the treated group was significantly delayed 
compared with that in the control group, and the time to reach total paralysis in the 
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treated group was delayed as well. The efficacy of trientine or ascorbate alone on FALS 
mice was also investigated (Nagano et al., 2003) when administered before or after the 
onset of the disease. The mice with a high dose of trientine (0.5% w/v) or ascorbate 
(0.8% w/w) administered before disease onset survived significantly longer by 62% than 
the control. None of the treatments affected the mean age of the onset, and none of the 
agents administered after the onset prolonged the survival. 
 
IV. The implication of flavonoids in protecting against ALS 
 
Flavonoids are naturally occurring polyphenolic compounds (Figure 1.3). They 
have antioxidant activities through their reactions with superoxide anions and lipid 
peroxides (Bors et al., 1990). Flavonoids were found to stabilize ascorbate against 
oxidation by different mechanisms. They can either bind metals that might catalyze 
ascorbate oxidation, or they can scavenge reactive oxygen species (Kuhnau J, 1976). 
Flavonoids can partition between aqueous and lipid phases due to their amphiphilic 
nature (Saija et al., 1995). This nature enables the flavonoids to cooperate with ascorbate 
to protect cell membranes (Bandy and Bechara, 2001). 
                    
          Quercetin                                 Catechin                                          Cyanidin 
 
         (Flavonol)                               (Flavanol)                                        (Anthocyanidin) 
 
Figure 1.2 Different classes of flavonoids 
In relation to the role of flavonoids in ALS, almost no research has been done in 
this area except for two studies. Genistein was suggested for its general neuroprotective 
effect. Genistein, a phytoestrogen, has both estrogen-dependent and estrogen-
 17
independent neuroprotective activities, and the authors suggested that it should be 
investigated as a prophylactic agent against pathologic conditions such as ALS and 
stroke (Trieu and Uckun, 1999). In another study with epigallocatechin gallate (EGCG), 
it was found that EGCG protects motor neurons isolated from wild type (WT) and G93A 
SOD1 mutant mice from oxidative stress-induced cytotoxicity. EGCG protects against 
cell death in these motor neurons by affecting upstream signalling through the 
phosphoinositide 3´ kinase/Akt and glycogen synthase kinase-3 pathway, as well as 
downstream signalling through cytochrome c release and caspase-3 activation (Koh et 
al., 2004). When differentiated WT and G93A cells pre-treated with EGCG were 
subsequently exposed to H2O2 –induced oxidative stress, the viability of both cells was 
significantly increased by 77% and 78%, respectively, compared to the cells treated with 
H2O2 only (Koh et al., 2004). 
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2. HYPOTHESES 
1- Zinc-deficient SOD (Cu-SOD), resulting from mutations or oxidative damage to 
the superoxide dismutase enzyme (SOD), gains function as an ascorbate oxidase 
that contributes to the pathology of ALS. 
2- Ascorbate as an antioxidant can compete with mutant SOD for scavenging the 
superoxide anions and consequently decrease the oxidative damage induced by 
the mutant SOD in ALS 
3- Flavonoids as antioxidants can act synergistically with ascorbate to decrease the 
oxidative damage induced by the mutant SOD in ALS, and at the same time 
protect against any pro-oxidant effects of ascorbate. 
 
 
3. OBJECTIVES 
 
3.1 In vitro study 
 
The first objective in the in vitro study is to investigate the effect of zinc-
extracted Cu/Zn SOD (Cu-SOD) and H2O2-damaged SOD on the rate of ascorbate 
oxidation by oxygen, to see if these enzyme preparations will accelerate ascorbate 
oxidation in comparison to the native SOD. 
The second objective is to test the effect of selected flavonoids such as catechin 
or quercetin and selected antioxidants such as uric acid on the rate of ascorbate oxidation 
in the presence of Cu-SOD. If Cu-SOD does accelerate ascorbate oxidation, we need to 
see if the flavonoids or uric acid might have any protective effect in vitro against 
ascorbate oxidation by Cu-SOD
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3.2 In vivo study 
 
The first objective in the in vivo study is to investigate the protective role of 
ascorbate as an antioxidant against the oxidative damage that is caused by the mutant 
Cu/Zn SOD in ALS, and to see if supplementation with ascorbate during the course of 
the disease will ameliorate the disease. Conversely, supplementation with ascorbate may 
have no effect or even worsen disease progression by increasing O2●¯ and H2O2 
production catalyzed by zinc-deficient SOD (Cu-SOD). Cu-SOD could increase O2●¯ 
and H2O2 by the following reactions: 
            Ascorbate + O2      Cu-SOD            Asc •⎯ + O2●¯                             (3.1) 
            2 O2●¯        Cu-SOD            H2O2                                                       (3.2) 
  or      Ascorbate + O2      Cu-SOD            dehydroascorbate + H2O2            (3.3) 
The second objective is to investigate the protective role of one of the flavonols 
(quercetin) as an antioxidant against the oxidative damage induced by the mutant Cu/Zn 
SOD in ALS, and to see if increasing quercetin intake during the course of the disease 
could affect the fate of ascorbate. Also quercetin may protect against the pro-oxidant 
effect of ascorbate.  
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4. MATERIALS AND METHODS 
 
4.1 Chemicals and Reagents 
 
The chemicals purchased from Sigma-Aldrich Canada Ltd (Oakville, ON, 
Canada) were: Cu/Zn superoxide dismutase (bovine erythrocyte), catalase (bovine liver), 
copper sulphate, zinc chloride, ascorbic acid, hydrogen peroxide, catechin, quercetin, 
uric acid (sodium salt), DMSO, ferric chloride, chelex 100 (sodium form), sodium salt of 
ascorbic acid, bovine serum albumin, sodium dodecyl sulfate, HEPES, monobasic and 
dibasic potassium phosphate, sodium deoxycholate, dithiothreitol, EDTA, tripotassium 
EDTA, BHT, potassium chloride, TBA, MDA, sodium potassium tartrate, potassium 
iodide, DTNB (5,5-dithiobisnitrobenzoic acid or Ellman’s reagent), glutathione 
reductase, GSH, and GSSG. Chemicals obtained from Alfa Aesar (Ward Hill, MA, 
USA) were: EGTA, and m-phosphoric acid. Chemicals purchased from EMD chemicals 
(Durham, NC) were: triton X-100, monobasic sodium phosphate, sodium chloride, 
glacial acetic acid, sulphuric acid, and HPLC grade methanol. Dibasic sodium phosphate 
was obtained from Spectrum Chemical Mfg. Corp. (Gardena, CA). Sodium acetate 
trihydrate, sodium hydroxide, pyridine, and n-butanol were obtained from EM Science 
(Gibbstown, N.J., USA). NADPH was obtained from Calbiochem (San Diego, CA, 
USA). 
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4.2 Methods for in vitro experiments  
 
4.2.1 Reagent preparation 
 
Buffers and other aqueous solutions were prepared in deionized, purified water 
(18 MΩ). The flavonoids catechin (20 mM) and quercetin (20 mM) were prepared by 
dissolving the powder in DMSO. 
 
4.2.2 Preparation of Zn-deficient SOD by dialysis procedure 
 
Spectrapor® membrane tubing was obtained from Spectrum Medical Industries 
(MW: 6-8,000 and diameter: 14.6 mm). To prepare the dialysis tubes, they were cut to 
the desired length, put into deionized, purified water, and let stand overnight. 
Afterwards, the dialysis tubes were transferred into chelex-treated 0.1 M phosphate 
buffer (pH 3.5) and let stand for several hours before use. Stocks of 0.1 M monobasic 
potassium phosphate buffer and 5 mM sodium acetate buffer were treated with chelex 
beads contained in a dialysis tube. After removal of the dialysis tube with chelex, 
phosphate and acetate buffers were adjusted to pH 3.5 and 4.0 respectively. All glass 
wares were washed with 1 mM EDTA and rinsed exhaustively with deionized water. 
The zinc was extracted from the enzyme according to previous procedures 
(Sampson and Beckman, 2001). The enzyme is made zinc deficient by dialysis against 2 
changes of 4 L of 0.1 M potassium phosphate buffer at pH 3.5 overnight at 4°C and then 
dialyzed against 5 mM sodium acetate buffer pH 3.5-4.0. This resulted in partial copper 
deficiency, which is corrected by incubation with a 10% excess (per mol subunit of 
enzyme) of cupric sulfate overnight at 4°C and brief (1-2 h) dialysis against 5 mM 
sodium acetate, pH 3.5 – 4.0, to remove unbound copper. 
 
4.2.3 Preparation of H2O2-damaged SOD preparations 
 
Oxidative damage was induced in two SOD enzyme preparations by treating the 
SOD native enzyme with hydrogen peroxide alone or hydrogen peroxide plus ascorbate 
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(previously neutralized to pH 7.2) in equal concentration(s) to the SOD enzyme (357 
mM) at physiological pH (50 mM potassium phosphate buffer pH 7.2). The treated 
enzyme in both preparations was incubated at room temperature (25°C) for 2 hours, and 
then it was dialyzed against 2 changes of 2L of 50 mM potassium phosphate buffer at 
pH 7.2, one overnight and the other for 8 hours at room temperature. 
 
4.2.4 Effects of SOD enzyme preparations on ascorbate oxidation  
 
The effect of different SOD enzyme preparations on the rate of ascorbate 
oxidation with comparison to the native SOD (nSOD) was tested. We tested the effect of 
three enzyme preparations; Zn-extracted SOD (Cu-SOD), H2O2-treated SOD (H2O2-
SOD), and ascorbate plus H2O2-treated SOD (A-H2O2 SOD) on the rate of ascorbate 
oxidation, and the effect of the metal chelators EDTA and EGTA on this rate. Final 
concentrations in the quartz cuvette (containing 1 ml 50 mM potassium phosphate 
buffer, pH 7.2, at 37°C) were: 0.16 mM ascorbate,10.68 mM nSOD, 21 mM H2O2-SOD, 
A-H2O2 SOD and Cu-SOD, 0.5 mM EDTA and EGTA,. The change in ascorbate 
absorbance was measured at λmax 265 nm. The experiment was done in duplicate under 
the same conditions and on the same day. 
 
4.3 Methods for in vivo experiments 
 
4.3.1 Animals and diets 
 
         Twenty female transgenic mice (6-8 week old) carrying a mutated human SOD1 
gene (JAX® Gemm® strain) weighing an average (±SEM) of 17.8g (±0.3g) plus six  
female control wild type mice (6-8 week old) weighing an average (±SEM) of 18g 
(±0.4g), were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). The strain 
distinction for the transgenic mice is B6SJL-TgN (SOD1-G93A) 1Gur/J, often referred 
to as G1H. The stock number of the transgenic mice is 002726. The strain distinction for 
the control wild type is B6SJL-Tg (SOD1)2Gur/J. The stock number of the control wild 
type mice is 002297. Transgenic mice were maintained as hemizygotes by crossing the 
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male transgenic mice with the female wild-type B6SJL. The transgene construct is 
composed of the human SOD1 gene carrying a glycine to alanine transition at position 
93 (G93A). The G93A mutation does not alter the superoxide dismutase activity of the 
protein. These transgenic mice express high levels of the transgene with a 4-fold 
increase in SOD activity, and exhibit a phenotype similar to amyotrophic lateral 
sclerosis (ALS) in humans. Hemizygous transgenic mice become paralyzed in one or 
more limbs and have a life span of approximately 19-23 weeks. Paralysis is due to loss 
of motor neurons from the spinal cord.  
    The mice were housed under constant temperature (22 ± 2°C) and were maintained on 
a 12 hour light: dark cycle (0700 to 1900 hours). The transgenic mice were randomly 
assigned to four experimental groups plus the wild type group (total five groups) and 
housed individually in stainless steel cages. The control diet was the AIN-93G diet 
(Reeves et al., 1993a) updated to meet 1995 NRC growth guidelines (NRC, 1995). Tert-
butylhydroquinone (tBHQ) was omitted to avoid the possibility that this antioxidant 
could mask the effect of the experimental treatment. The ingredients of the control diet 
are shown in Table 4.1. 
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 Table 4.1 The composition of the modified AIN-93G purified rodent diet with tBHQ 
omitted 1
Ingredient kcal/g g/kg kcal/kg 
Casein 3.58 200 716 
Sucrose 4 90 360 
Cornstarch 3.6 397.5 1431 
Dyetrose 2 3.8 132 501.6 
L-Cystine 4 3 12 
Cellulose 0 50 0 
Soybean Oil 9 70 630 
t-Butylhydroquinone 0 0 0 
Mineral Mix # 210025 3 0.88 35 30.8 
Vitamin Mix # 310025 4 3.87 10 38.7 
# 410750 to bring to 95 values 5 3.34 10 33.4 
Choline Bitartrate 0 2.5 0 
  1000.00 3753.5 
1Diets were purchased from Dyets Inc. (Bethlehem, PA, USA). 
2Dyetrose (Dyets, Bethlehem, PA, USA) is dextrinized cornstarch containing 90-94% 
tetrasaccharides. 
3Mineral Mix # 210025 (AIN-93G mineral mix prepared in sucrose finely powdered and 
used at 35g/kg diet), is shown in Table 4.2. 
4Vitamin Mix # 310025 (AIN-93VX vitamin mixture prepared in sucrose and used at 
10g/kg diet), is shown in Table 4.3. 
5# 410750 to bring to 95 values (Dyets AIN-93G rodent diet supplement to bring AIN-
93G diet formulations into compliance with 1995 NRC rat/mouse values and used at 
10g/kg diet), is shown in Table 4.4. 
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Table 4.2 AIN-93G Mineral Mix 
 
Ingredient g/kg 
Calcium carbonate 357.00 
Potassium Phosphate (monobasic) 196.00 
Potassium Citrate H2O 70.78 
Sodium Chloride 74.00 
Potassium Sulfate 46.60 
Magnesium Oxide 24.00 
Ferric Chloride, U.S.P. 6.06 
Zinc Carbonate 1.65 
Manganous Carbonate 0.63 
Cupric Carbonate 0.30 
Potassium Iodate 0.01 
Sodium Selenate 0.01025 
Ammonium Paramolybdate·4H2O 0.00795 
Sodium Metasilicate·9H2O 1.45 
Chromium Potassium Sulphate·12H2O 0.275 
Lithium Chloride 0.0174 
Boric Acid 0.0815 
Sodium Flouride 0.0635 
Nickle Carbonate 0.0318 
Ammonium Vanadate 0.0066 
Sucrose finely powdered 221.026 
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Table 4.3 AIN-93VX Vitamin Mixture* 
 
Ingredient g/kg 
Niacin 3.00 
Calcium Pantothenate 1.60 
Pyridoxine HCl 0.70 
Thiamine HCl 0.60 
Riboflavin 0.60 
Folic Acid 0.20 
Biotin 0.02 
Vitamin E Acetate (500 IU/g) 15.00 
Vitamin B12 (0.1%) 2.50 
Vitamin A Palmitate (500,000 IU/g) 0.80 
Vitamin D3 (400,000 IU/g) 0.25 
Vitamin K1/Dextrose Mix (10 mg/g) 7.50 
Sucrose 967.23 
 
Table 4.4 Dyets Inc. AIN-93G rodent diet supplement to bring AIN-93G diet 
formulations into compliance with 1995 NRC rat/mouse values* 
 
Ingredient g/kg 
L-Methionine 160.00 
Vitamin B12 (0.1%) 2.5 
Vitamin K1/Dextrose Mix (10 mg/g) 2.5 
Sucrose 835.00 
 
* Nutrient Requirements of Laboratory Animals. 4th Rev. Ed., National Research 
Council, 1995. 
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The mice arrived with no clinical signs of disease. The clinical signs for disease 
development were monitored once per week for the first week, increased to twice per 
week starting from the second week (7-9 weeks old), and finally increased to 3 times per 
week at the end of the feeding study (15-17 week old mice). Monitoring the disease 
progression was done by the following clinical signs (Nagano et al., 1999): 
1- The ability to grasp a pencil with hind limb when suspended by the tail. 
2- The number of the steps they miss in 2 minutes when they were put in a 
metabolic cage. 
3- Observations of activity, gait, and cage-climbing. 
The animals were sacrificed immediately if they reached any of the following endpoints: 
1- Inability to right themselves within 5 seconds when placed on their side. 
2- Inability to eat, drink or move toward food or water in a low dish. 
3- Loss of >10% of body weight in 24 hours. 
4- Notable lack of grooming, rough coat, or nasal/ocular discharge. 
5- Notably increased or labored breathing compared to wild-type controls. 
The animals were assigned into 5 experimental groups: 
1) Control wild type mice (CW), fed the modified AIN-93G diet (n=6). 
2) Control transgenic mice (CT), fed the modified AIN-93G diet (n=5). 
3) Ascorbate supplemented transgenic mice (A), fed the modified AIN-93G diet 
plus ascorbic acid (45 mmol/kg diet) (n=5). 
4) Quercetin supplemented transgenic mice (Q), fed the modified AIN-93G diet 
plus quercetin (29 mmol/kg diet) (n=5). 
5) Ascorbate plus quercetin supplemented transgenic mice (AQ), fed the modified 
AIN-93G diet plus ascorbic acid (45 mmol/kg diet), and quercetin (29 mmol/kg 
diet) (n=5). 
The AIN-93G diet was received in a powdered form, packed under vacuum by 
the manufacturing company, Dyets Inc. (Bethlehem, PA, USA). Ascorbic acid and 
quercetin were from the Sigma Chemical Company (St. Louis, MO, USA). The ascorbic 
acid and the quercetin were mixed with the powdered diet in a twin shell blender (“V 
blender”). For each kg of diet, it took 15 minutes of mixing and this was increased to 45 
min for making 2 kg diet. Preparing the diet was done under N2 gas and then the diet 
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was collected into Ziploc bags under N2 gas and stored at -20°C until needed. The mice 
in each group had free access to the assigned experimental diet and distilled tap water 
for 10 weeks. Weekly body weight was monitored and food intake was calculated four 
times during the feeding study. 
The mice were sacrificed on the same day at a point when several of the animals 
had developed paralysis in one of the hind limbs, a marker of disease development 
(Nagano et al., 1999) . One animal in the AQ group (ascorbate plus quercetin-fed group) 
was sacrificed 4 days early due to limb paralysis and prospective inability to move 
towards food or drink. The animals were first anaesthetized with isoflurane and then 
were killed by transcardial perfusion with phosphate-buffered saline (PBS) to eliminate 
blood from the tissues. The organs (liver, kidney, brain, heart and thigh muscles) were 
collected rapidly and then they were flash frozen in liquid nitrogen and stored at -80°C 
until use. For the spinal cord removal, we were successful in separating the whole intact 
spinal cord by using pressure from a syringe with a blunted needle, injecting PBS to 
push the spinal cord out from the thinnest area of the cord towards the thick, wider 
cervical area (as described in 
http://www.histosearch.com/histonet/Jun03/mousespinalcordremovalrev.html). The 
spinal cords were collected in 2 ml cryotubes, flash frozen in liquid nitrogen and stored 
at -80°C until use. All procedures were conducted in accordance with the Canadian 
Council of Animal Care guidelines for the care and use of laboratory animals and were 
approved by the Protocol Review Committee of the University Committee on Animal 
Care and Supply (Protocol # 20050134). 
 
4.3.2 Crushing and homogenization of tissues 
 
Prior to the biochemical analysis, all tissues were crushed into a fine powder 
under liquid nitrogen using Bio-Pulverizer model 59013N. The Bio-Pulverizer consists 
of a hole machined in a stainless steel base into which fits a special piston.  In a typical 
procedure, up to 1g of animal tissue is hard-frozen in liquid nitrogen and placed in the 
pre-chilled Bio-Pulverizer, and the tissue is pulverized with one or two blows to the 
pestle with a hammer. The mass of the stainless steel preserves the cold long enough to 
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complete the pulverization without adding additional liquid N2. The powdered tissues 
can be poured easily into cryotubes and stored at -80°C for subsequent homogenization 
or extraction procedures. The tissues afterwards were weighed in portions and 
homogenized in the appropriate homogenization media with a tissue grinder (Pellet 
Pestles® cordless motor, Kimble-Knotes # 749521-1590). The tissue grinder grinds soft 
tissues in Micro centrifuge tubes (1.5 ml) into homogenous solution.  
 
4.3.3 Tissue measurement of oxidative stress  
 
4.3. 3.1 Thiobarbituric acid reactive substances assay (TBARS) 
 
TBARS were measured in liver, brain, kidney, heart, thigh muscle and spinal 
cord as a marker of oxidative stress. The measurement of TBARS was adapted from the 
method of (Ohkawa et al., 1979). This method determines MDA and other reactive 
aldehyde levels by heating the samples in the presence of TBA at low pH, resulting in 
the formation of a pink chromophore with an absorption maximum near 532 nm (Abuja 
and Albertini, 2001). The procedure was scaled down for use with small samples (100µl 
of sample), and the TBA reaction products were extracted with an equal volume of the 
butanol/pyridine (15 butanol: 1 pyridine, v/v). BHT, and EGTA, previously neutralized 
to pH 7.2, were included in the tissue homogenization buffers to prevent artefactual 
formation of TBARS during sample preparation. 
 
4.3.3.1. A. Preparation of reagents 
 
Radioimmune precipitation assay buffer, pH 7.2 (RIPA buffer: 100 mM sodium 
phosphate buffer, 1.5 M sodium chloride, 1% triton X-100, 1% sodium deoxycholate, 2 
mM EDTA, 0.1% SDS) was prepared in deionized water. KCl/EGTA/BHT mixture was 
prepared by adding the following components: 2 mM EGTA (previously neutralized to 
pH 7.2), 0.02% BHT (prepared in DMSO) and 1.15% KCl). 8.1% SDS was prepared in 
deionized water. 0.8% TBA was prepared in deionized water with mild heating to 
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dissolve in water. 20% Acetic acid was adjusted to pH 3.5 using NaOH or KOH, and 
0.02% BHT was prepared in DMSO.  
Preparation of 150 mM MDA in 1% sulphuric acid was done by diluting 10.4 ml 
of sulphuric acid (96.5%) with 90 ml water (slowly adding the sulphuric acid to the 
water in the fume hood), then adding 0.227 ml of 1,1,3,3-tetraethoxypropane (97%) 
which will be hydrolyzed by the sulphuric acid to MDA. The stock solution was diluted 
in water by 100 times to obtain a final concentration of 1.5 mM MDA. Preparation of 
(15:1 v/v n-butanol/pyridine) was done by mixing, in the fume hood, 375 ml of butanol 
(99.4%) with 25 ml of pyridine (99.5%).  
 
4.3.3.1. B. Preparation of tissue homogenates for the TBARS assay 
 
For liver, brain, and spinal cord tissues, the samples were homogenized in 
KCl/EGTA/BHT mixture in the dilution ratio (9:1 v/w).The frozen tissues were first 
weighed and homogenized in KCl mixture (4:1 v/w), and then 5 parts of KCl mixture 
were added. For thigh muscle, heart and kidney tissues, the sample was homogenized in 
KCl mixture in the dilution ratio (4:1 v/w), and then 5 parts of RIPA buffer were added. 
Afterwards the muscle, heart and kidney homogenates were centrifuged at 15,000 x g for 
10 min at 4°C using an Allegra TM 25R Beckman Coulter centrifuge. For the liver, brain, 
and spinal cord tissues, the homogenates were assayed without prior centrifugation. 
 
4.3.3.1. C. TBARS assay procedures 
 
The measurements were done in duplicate for all tissue samples. Eppendorf tubes 
(2.0 mL) were prepared for incubation by adding the appropriate volumes of the 
following reagents: 8.1% SDS, 20% acetic acid, 0.8% TBA, and 0.02% BHT. Tissue 
homogenates were directly added to the prepared tubes (for assay blanks, the 
homogenization buffer was used without the sample) and the samples were heated at 
95°C for 60 min; then cooled in cold water. In the fumehood, 15:1 v/v n-
butanol/pyridine was added, and then the tubes were vortexed and centrifuged at 4000 x 
g for 10 min at 4°C using the Allegra TM 25R Beckman Coulter centrifuge. In the fume 
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hood, the organic layer was transferred to 1.5 ml cuvettes, and covered with Parafilm. 
The absorbance of this organic layer was read at 532 nm using a Beckman Coulter DU® 
640B spectrophotometer. 
 
4.3.3.2 Biuret protein assay 
 
Biuret protein assay was used to measure the protein concentration in tissue 
homogenates in order to make other measurements comparable. In the biuret assay, 
protein samples were combined with biuret reagent (32 mM sodium potassium tartrate, 
12 mM copper sulphate, 30 mM potassium iodide, 0.2 M NaOH). The copper ions form 
a complex with the amide groups in the proteins and create a blue color that was 
measured at 550 nm using a Beckman Coulter DU® 640B spectrophotometer. Protein 
concentrations of tissue homogenates were measured in duplicate by the biuret method 
(Layne E, 1957) using bovine serum albumin as a calibration standard.  
 
4.3.3.3 The ratio of GSH/GSSG, and protein thiols assay 
 
The tripeptide glutathione (γ-glutamylcysteinylglycine) is the major free thiol in 
most living cells and participates in diverse biological processes such as the detoxication 
of xenobiotics, removal of hydroperoxides, maintenance of the sulphydryl status of 
proteins, and modulation of enzyme activity by disulfide interchange. The oxidized form 
of GSH is glutathione disulfide (GSSG), and intracellular glutathione is effectively 
maintained in the reduced state by glutathione reductase linked to the NADPH/NADP+ 
system. When mammalian cells are exposed to increased oxidative stress, the ratio of 
GSH/GSSG will decrease as a consequence of GSSG accumulation. Measurement of the 
GSSG level or determination of the GSH/GSSG ratio is a useful indicator of oxidative 
stress (Akerboom and Sies, 1981). In protein SH and GSH assays, the sulfhydryl group 
reacts with DTNB (5,5-dithiobisnitrobenzoic acid or Ellman’s reagent) and produces a 
yellow colored 5-thionitrobenzoic acid (TNB), which is measured at 412 nm. In the 
GSSG assay, the GSSG is reduced by glutathione reductase using NADPH as a 
coenzyme, and the NADPH becomes oxidized to NADP+. The decrease of A340 was 
measured to determine the change in NADPH. 
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 4.3.3.3.1 Preparation of reagents 
 
10 mM DTNB was prepared in methanol. The other reagents such as, 3% m-
phosphoric acid, 10 mM NADPH, 250 U/ml glutathione reductase, 20 mM GSH, 10 mM 
GSSG, and 10% SDS, were prepared in deionized water. Potassium phosphate buffers 
with different pH (11, 8.5, and 7.6) were also prepared in deionized water. 
 
4.3.3.3.2 Preparation of tissue homogenates for glutathione assay 
 
Liver, thigh muscles and brain tissue samples were homogenized in 3% m-
phosphoric acid in the dilution ratio (9:1 v/w). The frozen tissues were first weighed and 
homogenized at 4:1 v/w, and then 5 parts of 3% m-phosphoric acid were added. 
Afterwards, the homogenates were centrifuged at 15,000 x g for 10 min at 4°C using an 
Allegra TM 25R Beckman Coulter centrifuge. The supernatant was used for GSH/GSSG 
assay and the pellet was used for protein thiols and biuret protein measurements. 
 
4.3.3.3.3 Reduced-glutathione (GSH) assay 
 
The measurements were done in duplicate for all tissue samples. The supernatant 
was mixed with potassium phosphate buffer (pH 11), and the absorbance was measured 
at 412 nm (A1). DTNB was added to the cuvette (0.1 mM final concentration), the 
samples were incubated in the dark for 20 min at room temperature, and then the second 
absorbance was measured at 412 nm (A2). The difference in absorbance before and after 
the addition of DTNB was calculated (A2-A1) and the GSH concentration was 
calculated using a standard curve. For the blank, 3% m-phosphoric acid was used instead 
of the supernatant. 
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4.3.3.3.4 Oxidized-glutathione (GSSG) assay 
 
The measurements were done in duplicate for all tissue samples. The supernatant 
was mixed with potassium phosphate buffer (pH 11), 0.2 mM NADPH was added and 
the absorbance was measured at 340 nm (A1). Glutathione reductase (0.2 U/ml) was 
added and the samples were incubated for 40 min at room temperature. Then, the second 
absorbance was measured at 340 nm (A2).The decrease in absorbance was calculated 
(A1-A2) and the GSSG concentration was calculated using a standard curve. For the 
blank, 3% m-phosphoric acid was used instead of the supernatant. 
 
4.3.3.3.5 Protein thiols assay 
 
The pellet was suspended in 26 µl 10% SDS, diluted with 850 µl potassium 
phosphate buffer (pH 8.5), mixed until complete dissolution, and then the absorbance 
was measured at 412 nm (A1). DTNB was added to the cuvette (0.1 mM final 
concentration), the samples were incubated in the dark for 20 min at room temperature, 
and then the second absorbance was measured at 412 nm (A2).The difference in 
absorbance before and after the addition of DTNB was calculated (A2-A1), and the 
protein thiols were calculated using reduced GSH as a calibration standard. For the 
blank, 10% SDS was used instead of the pellet and it was diluted with potassium 
phosphate buffer (pH 8.5) to the same volume as the samples. After dissolving the pellet 
and diluting with potassium phosphate buffer (pH 8.5), aliquots for the biuret protein 
assay were taken before doing the protein thiols assay. 
 
4.3.3.4 HPLC method for ascorbic acid determination 
 
Determination of total vitamin C (ascorbic acid plus dehydroascorbic acid) as 
well as ascorbic acid  and dehydroascorbic acid in brain, spinal cord and liver tissues 
was done using a validated HPLC method (Romeu-Nadal et al., 2006). The HPLC 
system consisted of Waters Model 590 pump system, Model 481 LC spectrophotometer, 
WatersTM Model 717 Plus autosampler and a Millennium data module (Millipore-
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Waters, Milford, MA, USA). All chromatographic separations were carried out on a 
reversed phase C18 column (Nova-Pak® C18 4µm 150 x 3.9 mm) maintained at 25°C. 
Brain, spinal cord, and liver tissue samples were homogenized in 0.56% m-
phosphoric acid in the dilution ratio (5:1 v/w). The measurements of vitamin C and total 
vitamin C were done in duplicate for all tissue samples. For the determination of total 
vitamin C content, dehydroascorbic acid was reduced to ascorbic acid with DL- DTT.  
100 µl of the tissue homogenates were mixed with 267 µl of DTT (100 mM), vortexed 
for 30 seconds, and then the mixture was incubated at room temperature (25°C) in the 
dark for 15 min. The homogenates were then centrifuged at 15,000 x g for 15 min at 4°C 
using an Allegra TM 25R Beckman Coulter centrifuge, and the supernatant was used for 
HPLC analysis. To analyze ascorbic acid, 100 µl of the tissue homogenates were 
directly centrifuged at 15,000 x g for 15 min, and the supernatant was used for analysis. 
Using the previous HPLC technique, ascorbic acid and total vitamin C were 
assayed by directly injecting 50 µl of the filtrate into the HPLC system. Isocratic 
chromatographic separation was done using a mobile phase composed of Milli-Q water 
with acetic acid (0.1%, v/v) and methanol in proportion of (80: 20) delivered at 0.5 
ml/min. Calibration curves were constructed from known concentrations of ascorbic acid 
solutions in 0.56% (w/v) m-phosphoric acid. Ascorbic acid was identified by comparing 
the retention time of the sample peak with that of the ascorbic acid standard at 254 nm.                           
 
4.3.4 Statistical Analysis 
 
Statistical analyses were performed using Excel software (Microsoft Office 2002). 
Results were expressed as the mean ± SEM. Differences among the four experimental 
groups were determined by one-way analysis of variance followed by Dunnett’s post 
hoc test for pair-wise multiple comparisons to the control transgenic SOD G93A group 
using GraphPad Prism 4.0 (GraphPad Software, San Diego, CA). The level of 
significance was set at p<0.05. Differences between the control-wild type group (CW) 
and the control transgenic SOD G93A (CT) group were determined by two-tailed 
unpaired t-test. A probability of less than 0.05 for the null hypothesis was considered 
significant. 
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5. RESULTS 
 
5.1 In vitro study 
 
5.1.1 The effect of zinc-extracted SOD (Cu-SOD) on ascorbate oxidation  
 
The in vitro experiments were conducted to see the effect of Cu-SOD on the 
initial rate of ascorbate air oxidation and to compare it to the rate of ascorbate oxidation. 
The zinc was extracted from the enzyme according to previous procedures (Sampson 
and Beckman, 2001). The results showed that Cu-SOD enzyme accelerates the rate of 
ascorbate oxidation, while native SOD has no effect (Figures 5.1 and 5.2). In Cu-SOD, 
the acceleration of ascorbate oxidation was only partially removed after adding EDTA. 
 
5.1.2 The effect of H2O2-treated SOD enzyme preparation on ascorbate oxidation  
 
Different H2O2-treated preparations of SOD were made with the hypothesis that 
in sporadic ALS, rather than having a mutation to the enzyme, the enzyme suffers 
oxidative damage that weakens its affinity for zinc and changes the catalytic activity. 
The native SOD enzyme was treated with H2O2 and ascorbate or H2O2 alone in 
concentrations equal to that of the SOD as described in the materials and methods 
section. The effects of these SOD preparations on ascorbate oxidation are shown in 
Figure 5.3. The results have shown that the rate of ascorbate oxidation was most highly 
accelerated with the ascorbate plus H2O2-treated enzyme (A-H2O2 SOD), followed by 
H2O2 treated SOD (H2O2 SOD), then finally the Zn-extracted SOD (Cu-SOD), while 
native SOD (nSOD) had no effect (note that nSOD was in lower concentration due to a 
limited supply for these experiments).
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Figure 5.1 The change in ascorbate absorbance against time in the presence of Zn-
extracted SOD (Cu-SOD) and native SOD (nSOD). The rate of ascorbate oxidation was 
measured at λmax 265 nm in 10 mM HEPES buffer, pH 7.2, 37°C, and with subsequent 
additions of SOD enzyme preparations in equimolar amounts and EDTA (as indicated 
by arrows). Concentrations in the cuvette were: 0.16 mM ascorbate, 21 mM nSOD or 21 
mM Cu-SOD, and 0.5 mM EDTA.  
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Figure 5.2 The rate of ascorbate oxidation in the presence of Zn-extracted SOD (Cu-
SOD) and native SOD (nSOD). The rate of ascorbate oxidation was measured at λmax 
265 nm in 10 mM HEPES buffer, pH 7.2, 37°C as in Figure 5.1, with ascorbate alone 
(before enzyme) and with subsequent additions of SOD enzyme preparations (after 
enzyme) and EDTA (after EDTA). Concentrations in the cuvette were: 0.16 mM 
ascorbate, 21 mM nSOD or 21 mM Cu-SOD, and 0.5 mM EDTA. The rates were 
calculated from the portions of the progress curve before and after additions, and the 
values are the mean of two experiments ± SEM. 
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The Cu-SOD preparation accelerated ascorbate oxidation less strongly in these 
experiments than in Figure 5.1 and 5.2, although this was with a separate Cu-SOD 
preparation and was in phosphate buffer rather than HEPES. Unlike with Zn-extracted 
SOD, the acceleration of ascorbate oxidation with the two H2O2 treated SOD was 
removed after adding EDTA.  
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Figure 5.3 The effect of different SOD preparations and EDTA on the rate of ascorbate 
oxidation. The rate of ascorbate oxidation was measured at λmax 265 nm in 50 mM 
potassium phosphate buffer, pH 7.2, 37°C, with ascorbate alone (before SOD), and with 
subsequent additions of SOD enzyme preparations (after SOD) and EDTA (after 
EDTA): (nSOD) native SOD enzyme, (H2O2 SOD) H2O2-treated enzyme, (A- H2O2 
SOD) H2O2 plus ascorbate treated enzyme, and (Cu-SOD) Zn-extracted SOD. 
Concentrations in the cuvette were: 0.16 mM ascorbate; 10.68 mM nSOD; 21 mM Cu-
SOD, 21 mM H2O2 SOD or 21 mM A- H2O2 SOD; and 0.5 mM EDTA. The values are 
the mean rates of two experiments ± SEM. 
 
The effect of different SOD preparations on the rate of ascorbate oxidation was 
further tested by adding EDTA first to the reaction media before adding the different 
SOD enzyme preparations. It was found that EDTA removed the acceleration of 
ascorbate oxidation in all SOD enzyme preparations except for the Zn-extracted one. 
The results are shown in Figure 5.4, and confirm that only the Cu-SOD persisted in 
catalyzing ascorbate oxidation in the presence of EDTA.  
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Figure 5.4 The effect of different SOD preparations on the rate of ascorbate oxidation in 
the presence of EDTA. The rate of ascorbate oxidation was measured at λmax 265 nm in 
50 mM potassium phosphate buffer, pH 7.2, 37°C, containing EDTA, with ascorbate 
alone (before SOD), and with subsequent additions of SOD enzyme preparations (after 
SOD): (nSOD) native SOD enzyme, (H2O2 SOD) H2O2-treated enzyme, (A- H2O2 
SOD) H2O2  plus ascorbate treated enzyme, and (Cu-SOD) Zn-extracted SOD. 
Concentrations in the cuvette were: 0.16 mM ascorbate; 10.68 mM nSOD; 21 mM Cu-
SOD, 21 mM H2O2 SOD or 21 mM A- H2O2 SOD; and 0.5 mM EDTA. The values are 
the mean rates of two experiments ± SEM. 
. 
 
The effect of another chelator (EGTA) on the rate of ascorbate oxidation with 
different SOD preparations was tested. The results are shown in Figure 5.5. The results 
have shown that EGTA worked better than EDTA as a chelator in preventing 
background autoxidation of ascorbate. Adding EGTA first to the reaction media before 
adding the different SOD enzyme preparations resulted in removing the acceleration of 
ascorbate oxidation in all SOD enzyme preparations except the Zn-extracted one. These 
results were consistent with what we have obtained with EDTA.  
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Figure 5.5 The effect of different SOD preparations on the rate of ascorbate oxidation in 
the presence of EGTA. The rate of ascorbate oxidation was measured at λmax 265 nm in 
50 mM potassium phosphate buffer, pH 7.2, 37°C, containing EGTA, with ascorbate 
alone (before SOD), and with subsequent additions of SOD enzyme preparations (after 
SOD): (nSOD) native SOD enzyme, (H2O2 SOD) H2O2-treated enzyme, (A- H2O2 
SOD) H2O2 plus ascorbate treated enzyme, and (Cu-SOD) Zn-extracted SOD. 
Concentrations in the cuvette were: 0.16 mM ascorbate; 10.68 mM nSOD; 21 mM Cu-
SOD, 21 mM H2O2 SOD or 21 mM A- H2O2 SOD; and 0.5 mM EGTA. The values are 
the mean rates of two experiments ± SEM. 
 
Since H2O2 produced during ascorbate oxidation may contribute to the rate of 
ascorbate oxidation, the effect of adding catalase enzyme with EGTA to the reaction 
media before adding different SOD enzyme preparations was tested. The results are 
shown in Figure 5.6. Comparing Figures 5.6 and 5.5, it was found that the removal of 
H2O2 by catalase enzyme in the presence of EGTA did not decrease the rate of ascorbate 
oxidation either before or after adding the SOD enzyme preparations. With native SOD, 
the presence of catalase appeared to reverse the effect of SOD, from inhibiting to 
accelerating ascorbate oxidation.  
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Figure 5.6 The effect of different SOD preparations on the rate of ascorbate 
consumption in presence of catalase and EGTA. The rate of ascorbate oxidation was 
measured at λmax 265 nm in 50 mM potassium phosphate buffer, pH 7.2, 37°C, 
containing EGTA and catalase, with ascorbate alone (before SOD), and with subsequent 
additions of SOD enzyme preparations (after SOD): (nSOD) native SOD enzyme, 
(H2O2 SOD) H2O2-treated enzyme, (A- H2O2 SOD) H2O2  plus ascorbate treated 
enzyme, and (Cu-SOD) Zn-extracted SOD. Concentrations in the cuvette were: 0.16 
mM ascorbate; 10.68 mM nSOD; 21 mM Cu-SOD, 21 mM H2O2 SOD or 21 mM A- 
H2O2 SOD; 0.5 mM EGTA; and 10 U/ml catalase. The values are the mean rates of two 
experiments ± SEM. 
. 
 
5.1.3 The effect of catechin and uric acid on ascorbate oxidation in the presence of 
Cu-SOD 
 
Some experiments with the flavonoids catechin and quercetin and with uric acid 
were conducted. All are efficient antioxidants and observed to protect ascorbate from 
oxidation in different situations (Ames et al., 1981), (Kuhnau J, 1976). The effect of 
catechin and uric acid on ascorbate oxidation in the presence of the Zn-extracted SOD 
(Cu-SOD) is shown in Figure 5.7. Uric acid was found to be protective by 67% against 
ascorbate oxidation by Cu-SOD, and catechin was protective by 72%. The results with 
quercetin were inconclusive due to overlapping absorbance of quercetin and ascorbate so 
that the extent to which the Cu-SOD enzyme was oxidizing ascorbate or quercetin was 
not clear (not shown). 
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Figure 5.7 The effect of catechin and uric acid on the rate of ascorbate oxidation in 
presence of Cu-SOD. The rate of ascorbate oxidation was measured at λmax 265 nm in 10 
mM HEPES buffer, pH 7.2, 37°C, containing EDTA, with ascorbate alone (before 
SOD), and with subsequent additions of Cu-SOD (after SOD) and catechin or uric acid 
(after catechin or uric acid). Concentrations in the cuvette were: 0.16 mM ascorbate, 15 
mM Cu-SOD, 34 mM tri potassium EDTA previously neutralized to pH 7.2, and 0.1 
mM catechin or 0.1 mM uric acid. The values are the mean rates of two experiments ± 
SEM. 
 
 
5.2 In vivo study 
 
5.2.1 Food consumption 
 
Food intake was calculated four times during the study, on weeks 3, 4, 8 and 9, 
and it was calculated for the whole group/day. The data are represented in Table 5.1. 
Food intake was increased in week 4 among all groups compared to other weeks. There 
was no apparent reason for this and I speculate that it might be because of the 
acclimatization of the animals to the new environment and the food. In comparing the 
food intakes of the different groups (average of the 4 measurements from each cage), 
there was no significant difference between them (Table 5.1). There were some 
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limitations in food intake calculation such as food spilling by the animals and estimating 
how much each mouse in a cage ate per day. 
 
Table 5.1 Food intake in different mice groups during the different four weeks* 
  CW CT A Q AQ 
Week 3 3.33 6.00 8.00 7.00 8.00 
Week 4 10.50 10.60 10.60 10.00 10.60 
Week 8 6.83 7.20 5.60 6.20 7.40 
Week 9 6.83 5.00 6.40 6.80 7.20 
Average 6.88±1.19 7.20±1.09 7.65±0.99 7.50±0.76 8.30±0.70
 
*Values are the amount of food consumed in grams divided by the number of animals in 
that cage. Statistical analysis on the average food intakes over the 4 weeks was done by 
one-way ANOVA followed by Dunnett’s Multiple Comparison Test, which found no 
significant difference in food intake among the transgenic animals compared to control 
wild-type (p>0.05).  
 
 5.2.2 Body weight in mice 
 
The weight of the animal was monitored weekly during the whole study. The 
body weight results are represented in Figure 5.8. There was a significant decrease in the 
body weight of (CT) control transgenic mice starting from the 7th week (p<0.05) 
compared to (CW) control wild type group (Figure 5.9). Also there was significant 
decrease in the body weight of all the transgenic mice groups starting from the 9th week 
(p<0.05) in comparison to (CW) control wild type group (Figure 5.10). The loss in body 
weight was not related to the food intake as there was not a significant decrease in food 
intake despite the significant decrease in body weight. 
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Figure 5.8 The mice body weights over the 10 weeks of the study. (CW) control wild 
type group, (CT) control transgenic SOD G93A mice, (A) ascorbate-fed transgenic 
mice, (Q) quercetin-fed transgenic, and (AQ) ascorbate + quercetin-fed transgenic. Body 
weight was calculated as the mean ± SEM; n=5 for all groups except for the control-wild 
type (CW), n=6. 
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Figure 5.9 The body weight of mice in the 8th week of the study. (CW) control wild type 
group, (CT) control transgenic SOD G93A mice, (A) ascorbate-fed transgenic mice, (Q) 
quercetin-fed transgenic, and (AQ) ascorbate + quercetin-fed transgenic. Body weight 
was calculated as the mean ± SEM; n=5 for all groups except for the control wild type 
(CW), n=6. Statistical analysis was done by one-way ANOVA followed by Dunnett’s 
multiple comparison tests which found significant decrease only in the body weight of  
(CT) control transgenic SOD G93A mice compared to the (CW) control-wild type group 
(*p<0.01). 
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Figure 5.10 The body weight of mice in the 10th week of the study. (CW) control wild 
type group, (CT) control transgenic SOD G93A mice, (A) ascorbate-fed transgenic 
mice, (Q) quercetin-fed transgenic, and (AQ) ascorbate + quercetin-fed transgenic. Body 
weight was calculated as the mean ± SEM; n=5 for all groups except for the control wild 
type (CW), n=6. Statistical analysis was done by one-way ANOVA followed by 
Dunnett’s multiple comparison tests which found a significant decrease in the body 
weight of  all transgenic SOD G93A mice groups in comparison to (CW) control-wild 
type group (*p<0.01). 
 
5.2.3 Monitoring disease development in mice 
 
    The mice were monitored for development of disease signs and symptoms 
twice per week starting from the third week until the 7th week, and then 3 times per week 
for the 8th and 9th week. In the last week, mice were monitored on a daily basis as they 
started to develop most of the signs and we did not want them to reach an end stage or to 
suffer. The test that we used to monitor the signs of the disease was their ability to grasp 
a pencil with their hind limb when they were suspended by the tail. We graded their 
response as good (having no problem in holding the pencil once we suspend them by 
their tail), having some difficulty (struggling for sometime, but finally could hold the 
pencil), or having much difficulty (struggling a lot and couldn’t hold the pencil as their 
hind limb was too weak to do this movement).  
Another test was used to monitor the mice activity level by counting the number 
of steps they miss over 2 minutes when they were put in a metabolic cage with a wire 
grid bottom. This test was started on the 6th week (twice per week) and then it was 
stopped at the 9th week as their activity level was very low at that time. The mice were 
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also watched closely every day while feeding them and monitoring their activity level by 
the way they moved and climbed over the cage lid. Upon subjective observation, the 
CW group had the highest activity level during the whole study followed by Q group, 
then AQ, then A, and finally CT with the lowest activity level. In the 10th week, one 
mouse of AQ group started to develop the disease more rapidly than the others and 
started to get paralyzed in one hind limb, so i had to sacrifice it with one of the CW 
group. This was done 4 days before sacrificing all groups. Also another mouse was 
sacrificed from the same group (AQ) one day early due to a bad wound in its tail and 
swelling in its leg. The next day, all the mice were sacrificed. Table 5.2 represents the 
number of animals in each group that became paralyzed in one limb (diseased) versus 
the animals that did not develop advanced signs or symptoms at the time of sacrifice 
(healthy). 
 
Table 5.2 The number of diseased versus healthy mice in each group at the time of 
sacrifice 
  CT A Q AQ Total 
Diseased 3 2 1 3 9 
Healthy 2 3 4 2 11 
Total number of mice 5 5 5 5 20 
 
5.2.4 Comparisons between transgenic and wild type mice  
 
 
Different measurements of oxidative stress were compared between control wild 
type (CW) and control transgenic SOD G93A (CT) mice (Table 5.3). There was 47% 
increase (p<0.05) in liver TBARS in control transgenic SOD G93A (CT) mice compared 
to control wild type (CW) mice. There was also 136% increase (p<0.05) in GSH/GSSG 
ratio in the muscle of CT mice compared to CW mice. 
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 Table 5.3 Comparison between different measurements in control wild type (CW) and 
control transgenic SOD G93A (CT) mice 
 
 Brain Liver Thigh muscle 
 CW CT CW CT CW CT 
GSH  
(mmol/mg 
protein) 
5.47±0.68 3.8±0.72 6.91±2.7 7.44±1.47 1.13±0.42 2.4±0.46 
GSSG  
(mmol/mg 
protein) 
1.53±0.50 1.85±0.61 2.95±1.38 1.26±0.35 0.88±0.22 0.85±0.22 
Total GSH 
(GSH+2GSSG)  
(mmol/mg 
protein) 
8.52±1.53 7.51±1.61 12.80±4.59 9.96±1.49 2.49±0.75 4.09±0.85 
GSH/GSSG 6.89±3.01 4.16±2.47 4.30±1.34 9.39±3.73 1.43±0.36 3.37±0.84* 
Protein thiols  
(mmol/mg 
protein) 
12.10±2.95 16.5±3.37 8.67±4.25 5.65±2.04 4.79±1.76 5.03±1.00 
TBARS  
(mmol/mg 
protein) 
0.308±0.071 0.328±0.058 0.047±0.005 0.069±0.007* 0.010±0.001 0.016±0.004 
 Kidney Heart Spinal cord 
TBARS  
(mmol/mg 
protein) 
0.006±0.001 0.008±0.001 0.080±0.081 0.051±0.009 0.626±0.104 0.326±0.074 
 
Each value is the mean ± SEM; n=6 for CW and n=5 for CT. Statistical analysis was 
done using an unpaired two-tailed t-test. 
*Significant difference in CT (p<0.05) group in comparison to CW group. 
 
The levels of vitamin C, oxidized-vitamin C and total vitamin C levels were 
compared in brain, spinal cord, and liver tissues between control wild type (CW) and 
control transgenic SOD G93A (CT) mice. The data are summarized in Table 5.4. The 
level of oxidized-vitamin C in spinal cord was found to be unexpectedly lower by 60% 
(p<0.05) in control transgenic SOD G93A (CT) mice compared to control wild type 
(CW). However, the level of oxidized-vitamin C in spinal cord was very low in 
comparison to other tissues. The most remarkable result was that oxidized-vitamin C in 
liver of control transgenic SOD G93A (CT) mice was 29-times that of (p<0.01) control 
wild type (CW). The levels of vitamin C and total vitamin C in liver were also 
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significantly increased (43%, p<0.05 and 460%, p<0.01) in control transgenic SOD 
G93A (CT) mice compared to control wild type (CW).  It should be noted that prior to 
these measurements (but not any others), the liver tissue had thawed in a malfunction of 
the -80°C freezer. It could be that some of the ascorbate oxidation occurred during this 
period, but even so it shows a large difference between transgenic and wild type livers 
(both of which thawed). 
 
Table 5.4 Comparison between vitamin C, oxidized-vitamin C and total vitamin C in 
control wild type (CW) and control transgenic SOD G93A (CT) mice 
 
  
  Brain Spinal cord Liver 
 CW CT CW CT CW CT 
Vitamin C  
(µmol/mg 
tissue) 7.9±0.3 7.8±0.3 3.4±0.4 3.1±0.1 6.1±0.6 8.7±1.0* 
Total Vitamin C 
(µmol/mg 
tissue) 11.1±0.5 10.6±0.6 4.1±0.4 3.4±1.5 7.2±0.7 40.4±4.5** 
Dehydroascorbic 
acid (µmol/mg 
tissue) 3.2±0.2 2.8±0.2 0.7±0.1 0.3±0.1* 1.1±0.2 31.7±3.5** 
 
Each value is the mean ± SEM; n=6 for CW and n=5 for CT. Statistical analysis was 
done using an unpaired two-tailed t-test. * Significant difference in CT (p<0.05) group 
in comparison to CW group. ** Significant difference in CT (p<0.0001) group in 
comparison to CW group. 
 
 
5.2.5 Comparisons of Dietary Treatments 
 
5.2.5.1 TBARS assay 
 
TBARS assays were done on brain, liver, thigh muscle, kidney, heart and spinal 
cord from transgenic SOD G93A mice fed different diets (Figure 5.11). The highest 
TBARS level was found in spinal cord tissue, in which there was a significant 98% 
increase (p<0.05) in TBARS in the ascorbate-fed group (A) in comparison to control 
transgenic mice (CT). Regarding other tissues there was no significant difference 
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between the different dietary treatment groups in comparison to (CT) control transgenic 
mice. 
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Figure 5.11 TBARS assays in different tissues. Assays of TBARS as MDA equivalents 
were done on different tissues from SOD G93A transgenic mice fed the following diets 
for 10 weeks: (CT) control-diet transgenic SOD G93A mice, (A) ascorbate-
supplemented, (Q) quercetin-supplemented, and (AQ) ascorbate + quercetin-
supplemented. Each value is the mean ± SEM; n=5. Statistical analysis was done by 
one-way ANOVA followed by Dunnett’s multiple comparison tests (* p<0.05). 
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5.2.5.2 GSH assay 
 
Reduced-glutathione was measured in brain, liver and thigh muscle. The data are 
represented in Figure 5.12. The highest level of GSH was found in liver tissue. There 
was no significant difference between the different dietary treatment groups in 
comparison to (CT) control transgenic mice SOD G93A group.  
CT A Q AQ
0
1
2
3
4
5
G
SH
 (m
m
ol
/m
g 
pr
ot
ei
n)
Brain Liver
Thigh muscle
CT A Q AQ
0.0
2.5
5.0
7.5
G
SH
 (m
m
ol
m
g 
pr
ot
ei
n)
CT A Q AQ
0
10
20
30
40
G
SH
 (m
m
ol
/m
g 
pr
ot
ei
n)
 
Figure 5.12 GSH assays in different tissues. Assays of GSH were done on different 
tissues from SOD G93A transgenic mice fed the following diets for 10 weeks: (CT) 
control-diet transgenic SOD G93A mice, (A) ascorbate-supplemented, (Q) quercetin-
supplemented, and (AQ) ascorbate + quercetin-supplemented. Each value is the mean ± 
SEM; n=5. Statistical analysis was done by one-way ANOVA followed by Dunnett’s 
multiple comparison tests. 
 
5.2.5.3 GSSG assay 
 
Oxidized-glutathione was measured in brain, liver, and thigh muscle. The data 
are represented in Figure 5.13. There was no significant difference between the different 
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dietary treatment groups in comparison to the (CT) control transgenic mice SOD G93A 
group.  
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Figure 5.13 GSSG assays in different tissues. Assays of GSSG were done on different 
tissues from SOD G93A transgenic mice fed the following diets for 10 weeks: (CT) 
control-diet transgenic SOD G93A mice, (A) ascorbate-supplemented, (Q) quercetin-
supplemented, and (AQ) ascorbate + quercetin-supplemented. Each value is the mean ± 
SEM; n=5. Statistical analysis was done by one-way ANOVA followed by Dunnett’s 
multiple comparison tests. 
 
 
5.2.5.4 The total glutathione (GSH+2GSSG) 
 
Total glutathione was calculated in brain, liver, and thigh muscle. The data are 
represented in Figure 5.14. The highest level of total glutathione was found in liver 
tissue. There was no significant difference between the different dietary treatment 
groups in comparison to the (CT) control transgenic mice SOD G93A group.    
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Figure 5.14 Total glutathione (GSH+2GSSG) in different tissues. (CT) control 
transgenic SOD G93A mice, (A) ascorbate-fed transgenic mice, (Q) quercetin-fed 
transgenic, and (AQ) ascorbate + quercetin-fed transgenic. Each value is the mean ± 
SEM; n=5. Statistical analysis was done by one-way ANOVA followed by Dunnett’s 
multiple comparison tests. 
 
 
5.2.5.5 The ratio between reduced and oxidized-glutathione (GSH/GSSG) 
 
The ratio between reduced and oxidized-glutathione (GSH/GSSG) was 
calculated in brain, liver, and thigh muscle. The data are represented in Figure 5.15. The 
highest ratio of reduced to oxidized-glutathione (GSH/GSSG) was found in liver tissue. 
There was no significant difference between the different dietary treatment groups in 
comparison to the (CT) control transgenic mice SOD G93A group.  
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Figure 5.15 The ratio between reduced and oxidized-glutathione (GSH/GSSG) in 
different tissues. (CT) control transgenic SOD G93A mice, (A) ascorbate-fed transgenic 
mice, (Q) quercetin-fed transgenic, and (AQ) ascorbate + quercetin-fed transgenic. Each 
value is the mean ± SEM; n=5. Statistical analysis was done by one-way ANOVA 
followed by Dunnett’s multiple comparison tests. 
 
5.2.5.6 The measurement of protein thiols 
 
The measurement of total protein thiols was done in brain, liver, and thigh 
muscle. The results are represented in Figure 5.16. In brain tissues, the total protein 
thiols were significantly decreased (p<0.05) by 58% and 56% in both the (AQ) ascorbate 
+ quercetin-fed transgenic mice group and in (Q) quercetin-fed transgenic mice group in 
comparison to (CT) control transgenic mice SOD G93A group. 
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Figure 5.16 The total protein thiols in different tissues. Assays of total protein thiols 
were done on different tissues from SOD G93A transgenic mice fed the following diets 
for 10 weeks: (CT) control-diet transgenic SOD G93A mice, (A) ascorbate-
supplemented, (Q) quercetin-supplemented, and (AQ) ascorbate + quercetin-
supplemented. Each value is the mean ± SEM; n=5. Statistical analysis was done by 
one-way ANOVA followed by Dunnett’s multiple comparison tests (* p<0.05). 
 
5.2.5.7 The measurement of ascorbic acid and total vitamin C  
 
The concentration of ascorbic acid and total vitamin C in brain, spinal cord, and 
liver from the different dietary groups was measured using HPLC. The highest 
concentration of vitamin C was found in liver tissue (Figure 5.17). In liver tissue the 
level of vitamin C was significantly lower (p<0.05) by 40% in (Q) quercetin-fed 
transgenic mice group compared to the (CT) control transgenic mice SOD G93A group. 
In brain and spinal cord, there was no significant difference in vitamin C concentrations 
between the different dietary treatment groups in comparison to the (CT) control 
transgenic mice SOD G93A group. 
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Figure 5.17 Vitamin C concentrations in different tissues. Assays of vitamin C were 
done on different tissues from SOD G93A transgenic mice fed the following diets for 10 
weeks: (CT) control-diet transgenic SOD G93A mice, (A) ascorbate-supplemented, (Q) 
quercetin-supplemented, and (AQ) ascorbate + quercetin-supplemented. Each value is 
the mean ± SEM; n=5. Statistical analysis was done by one-way ANOVA followed by 
Dunnett’s multiple comparison tests (* p<0.05). 
 
 
         The concentration of total vitamin C was also measured in brain, spinal cord, and 
liver homogenates (Figure 5.18). The highest level of total vitamin C was found in liver 
tissue. Also the level of total vitamin C in liver was found to be significantly lower 
(p<0.05) by 40% in (Q) quercetin-fed transgenic mice group compared to (CT) control 
transgenic mice SOD G93A group. In brain and spinal cord there was no significant 
difference in total vitamin C concentrations between the different dietary treatment 
groups in comparison to (CT) control transgenic mice SOD G93A group. 
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Figure 5.18 Total vitamin C concentrations in different tissues. Assays of total vitamin 
C were done on different tissues from SOD G93A transgenic mice fed the following 
diets for 10 weeks: (CT) control-diet transgenic SOD G93A mice, (A) ascorbate-
supplemented, (Q) quercetin-supplemented, and (AQ) ascorbate + quercetin-
supplemented.. Each value is the mean ± SEM; n=5. Statistical analysis was done by 
one-way ANOVA followed by Dunnett’s multiple comparison tests (* p<0.05). 
 
         The concentration of oxidized-vitamin C (dehydroascorbic acid) was calculated in 
brain, spinal cord and liver tissues (Figure 5.19). Much higher levels of oxidized-vitamin 
C were found in liver tissue. The level of oxidized-vitamin C in liver was found to be 
significantly lower (p<0.05) by 40% in (Q) quercetin-fed transgenic mice compared to 
(CT) control transgenic mice. In spinal cord there was a 250% increase (p<0.05) in 
oxidized-vitamin C in the (AQ) ascorbate + quercetin-fed transgenic mice group 
compared to the (CT) control transgenic mice SOD G93A group. In brain there was no 
significant difference in oxidized-vitamin C concentrations between the different dietary 
treatment groups in comparison to (CT) control transgenic mice SOD G93A group.  
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Figure 5.19 Oxidized-vitamin C concentrations in different tissues. (CT) control 
transgenic SOD G93A mice, (A) ascorbate-fed transgenic mice, (Q) quercetin-fed 
transgenic, and (AQ) ascorbate + quercetin-fed transgenic. Each value is the mean ± 
SEM; n=5. Statistical analysis was done by one-way ANOVA followed by Dunnett’s 
multiple comparison tests (* p<0.05). 
 
 
5.2.6 Comparisons of healthy versus diseased animals 
  
5.2.6.1 TBARS assay 
 
Different measurements of oxidative stress was compared between transgenic 
SOD G93A mice from all four treatment groups which developed advanced signs of 
disease at the time of sacrificing the animals (“diseased”) and the transgenic SOD G93A 
mice which had no advanced signs of disease at the time of sacrifice (“healthy”). For 
TBARS, the data are shown in Figure 5.20. There was no significant differences in 
TBARS levels between the diseased and the healthy transgenic SOD G93A mice in any 
of the tissues. 
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 Figure 5.20 TBARS level in different tissues in healthy versus diseased transgenic SOD 
G93A mice. TBARS was measured as described in materials and methods. The data are 
represented as the mean ± SEM; n=9 for the diseased mice and n=11 for the healthy 
mice. Statistical analysis was done using an unpaired two-tailed t-test. 
 
5.2.6.2 GSH assay 
 
For GSH measurement, the data are shown in Figure 5.21. In muscle tissue, there 
was a 120% increase (p<0.05) in GSH level in the diseased transgenic SOD G93A mice 
compared to the healthy mice.  
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Figure 5.21 GSH measurements in different tissues in healthy versus diseased 
transgenic SOD G93A mice. The data are represented as the mean ± SEM; n=9 for the 
diseased mice and n=11 for the healthy mice. Statistical analysis was done using an 
unpaired two-tailed t-test (*p< 0.05). 
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5.2.6.3 GSSG assay 
 
For GSSG measurement, the data are shown in Figure 5.22. The GSSG level was 
generally higher in diseased transgenic SOD G93A mice compared to healthy transgenic 
SOD G93A mice in all tissues. The highest GSSG level was found in liver tissue but it 
was not significantly higher in diseased mice compared to the healthy transgenic SOD 
G93A mice. In muscle tissue there was a 130% increase (p<0.05) in the GSSG level in 
diseased transgenic SOD G93A mice compared to the healthy mice.  
 
5.2.6.4 The total glutathione (GSH+2GSSG) 
 
The total glutathione (GSH+GSSG) was calculated in diseased transgenic SOD 
G93A mice and it was compared to the healthy transgenic SOD G93A mice. The data 
are shown in Figure 5.23. The total glutathione was the highest in liver tissue, but it was 
not significantly different between the diseased transgenic SOD G93A mice compared to 
the healthy mice. The total glutathione level was 130% higher (p<0.05) in diseased 
transgenic SOD G93A mice compared to the healthy mice in muscle tissue. 
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Figure 5.22 GSSG measurements in different tissues in healthy versus diseased 
transgenic SOD G93A mice. The data are represented as the mean ± SEM; n=9 for the 
diseased mice and n=11 for the healthy mice. Statistical analysis was done using an 
unpaired two-tailed t-test (*p<0.05). 
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Figure 5.23 The total glutathione (GSH+2GSSG) in different tissues in healthy versus 
diseased transgenic SOD G93A mice. The data are represented as the mean ± SEM; n=9 
for the diseased mice and n=11 for the healthy mice. Statistical analysis was done using 
an unpaired two-tailed t-test (*p< 0.05). 
 
5.2.6.5 The ratio between reduced and oxidized-glutathione (GSH/GSSG) 
 
The ratio between reduced and oxidized glutathione (GSH/GSSG) was calculated 
in diseased transgenic SOD G93A mice and it was compared to the healthy mice. The 
data are shown in Figure 5.24. There was no significant difference in the ratio 
(GSH/GSSG) between diseased transgenic SOD G93A mice and healthy mice in all 
tissues. 
 
5.2.6.6 The measurement of protein thiols 
 
For the total protein thiols, the data are shown in Figure 5.25. There was no 
significant difference in the total protein thiols between diseased transgenic SOD G93A 
mice versus the healthy mice in all tissues. 
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Figure 5.24 The ratio between reduced and oxidized-glutathione (GSH/GSSG) in 
different tissues in healthy versus diseased transgenic SOD G93A mice. The data are 
represented as the mean ± SEM; n=9 for the diseased mice and n=11 for the healthy 
mice. Statistical analysis was done using an unpaired two-tailed t-test. 
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Figure 5.25 The total protein thiols in different tissues in healthy versus diseased 
transgenic SOD G93A mice. The data are represented as the mean ± SEM; n=9 for the 
diseased mice and n=11 for the healthy mice. Statistical analysis was done using an 
unpaired two-tailed t-test. 
 
 
5.2.6.7 The measurement of ascorbic acid and total vitamin C 
 
The levels of vitamin C, total vitamin C and oxidized-vitamin C 
(dehydroascorbic acid) were compared between diseased and healthy transgenic SOD 
G93A mice. The data for vitamin C are represented in Figure 5.26. The level of vitamin 
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C was generally higher in diseased transgenic SOD G93A mice compared to healthy 
mice in all tissues, but not significantly in brain or liver tissues. In spinal cord tissue 
there was 40% increase (p<0.01) in vitamin C level in diseased transgenic SOD G93A 
mice compared to the healthy mice.  
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Figure 5.26 Vitamin C level in different tissues in healthy versus diseased transgenic 
SOD G93A mice. The data are represented as the mean ± SEM; n=9 for the diseased 
mice and n=11 for the healthy mice. Statistical analysis was done using an unpaired two-
tailed t-test (**p<0.01). 
 
The level of total vitamin C was compared between diseased and healthy 
transgenic SOD G93A mice. The data are represented in Figure 5.27. The level of total 
vitamin C was generally higher in diseased transgenic SOD G93A mice compared to the 
healthy mice in all tissues, but not significantly in liver. In both brain and spinal cord 
tissues, there were significant increases (p<0.01) (16% and 23%) in total vitamin C in 
diseased transgenic SOD G93A mice compared to the healthy mice.  
 
The level of oxidized-vitamin C (dehydroascorbic acid) was also compared in 
brain, spinal cord and liver tissues between diseased and healthy transgenic SOD G93A 
mice. The data are represented in Figure 5.28. There was no significant difference 
between diseased and healthy transgenic SOD G93A mice.  
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Figure 5.27 Total vitamin C levels in different tissues in healthy versus diseased 
transgenic SOD G93A mice. The data are represented as the mean ± SEM; n=9 for the 
diseased mice and n=11 for the healthy mice. Statistical analysis was done using an 
unpaired two-tailed t-test (**p<0.01). 
 
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
Brain Spinal cord LiverO
xi
di
ze
d 
vi
ta
m
in
 C
 (µ
m
ol
/m
g 
tis
su
e)
Healthy
Diseased
 
Figure 5.28 Oxidized-vitamin C level in different tissues in healthy versus diseased 
transgenic SOD G93A mice. The data are represented as the mean ± SEM; n=9 for the 
diseased mice and n=11 for the healthy mice. Statistical analysis was done using an 
unpaired two-tailed t-test.
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6. DISCUSSION 
 
ALS is one of the most serious neurodegenerative diseases. It is characterized by 
loss of both upper and lower motor neurons (Julien JP, 2001). There are two distinct 
types of ALS: familial ALS which represents 10% of ALS cases, and sporadic ALS with 
the majority of cases (90%) (Julien JP, 2001). The exact cause of ALS is still unknown, 
but there have been different hypotheses trying to explain the mystery behind this 
serious illness. The only proven cause until now is the mutation in the gene expressing 
the superoxide dismutase enzyme (SOD1) (Rosen et al., 1993). This mutation occurs in 
only 20% of the familial cases.  Different hypotheses have been proposed to explain the 
toxicity of the mutant SOD1 in ALS. One of these hypotheses is that the mutant enzyme 
can release zinc from its binding site, as the affinity of the mutant enzyme for zinc is 
decreased. Once the enzyme is zinc-deficient, it gains an ability to induce oxidative 
damage (Beckman et al., 2001).  
Beckman’s group suggested that zinc loss from mutant SOD enzyme leads to 
apoptosis of motor neurons by a mechanism involving peroxynitrite (Beckman et al., 
2001). They hypothesized that zinc-deficient SOD can steal electrons from cellular 
reductants such as ascorbate or GSH and transfer them to oxygen to produce a bound 
superoxide intermediate. The superoxide intermediate in turn can react with nitric oxide 
to produce peroxynitrite, which induces cellular damage and provokes apoptosis.  
In the studies of this thesis, we investigated whether zinc-deficient SOD, resulting from 
mutations or oxidative damage to the superoxide dismutase enzyme (SOD), gains 
function as an ascorbate oxidase that contributes to the pathology of ALS. We proposed 
that the zinc-deficient enzyme can either catalyze the transfer of two electrons from 
ascorbate to oxygen to produce hydrogen peroxide as an end product, or in single 
electron steps, it can transfer electrons from ascorbate to oxygen and release free 
superoxide anion which then dismutates to hydrogen peroxide. By either 
 64
mechanism, the aerobic oxidation of ascorbate in the presence of zinc-deficient SOD 
enzyme leads to production of hydrogen peroxide which contributes to the toxicity of 
zinc-deficient SOD in ALS. This differs from the hypothesis of Beckman et al., 2001 in 
that it does not involve the need for nitric oxide. 
 
6.1 In vitro objectives 
 
6.1.1 The effect of zinc-extracted SOD (Cu-SOD) on ascorbate oxidation  
 
The in vitro experiments supported the hypothesis that zinc-deficient SOD can 
act as an ascorbate oxidase, showing that Zn-extracted SOD (Cu-SOD) accelerated the 
rate of ascorbate aerobic oxidation 5-fold, while native SOD had no effect (Figures 5.1 
and 5.2). The acceleration by Cu-SOD was greater in HEPES buffer than in phosphate 
buffer (Figure 5.2 versus Figure 5.3), partly due to greater background ascorbate 
autoxidation in phosphate buffer. With Cu-SOD, the acceleration of ascorbate oxidation 
was only partially removed after adding EDTA in HEPES buffer (Figure 5.2), and 
unaffected by EDTA in phosphate buffer (Figures 5.3 and 5.4). The lack of inhibition by 
EDTA means that it is copper that is tightly bound to the enzyme and not copper 
released to the solution that accelerates ascorbate oxidation. This means that after zinc 
loss from the active site of the enzyme, copper becomes more exposed and thus prone to 
reduction by ascorbate and re-oxidation by oxygen. These experiments also show that 
Cu-SOD is able to catalyze substantial ascorbate oxidation with oxygen alone, 
producing H2O2 as the presumed end product. These experiments suggest a different or 
alternative reaction that unlike the one suggested by Beckman et al 2001, does not need 
nitric oxide and produces H2O2 instead of peroxynitrite. 
Part of our hypothesis was that the SOD enzymes in sporadic ALS, rather than 
having a mutation, suffer oxidative damage that weakens the zinc affinity and changes 
the catalytic activity. In order to test this hypothesis, different H2O2-treated preparations 
of SOD were made, and the effects of these SOD preparations on ascorbate oxidation 
were tested. The results showed that the rate of ascorbate oxidation was most highly 
accelerated with ascorbate plus H2O2-treated enzyme (A-H2O2 SOD), followed by H2O2 
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treated SOD (H2O2 SOD), then finally Zn-extracted SOD (Cu-SOD), while native SOD 
(nSOD) decreased the rate from that of the baseline (Figure 5.3). These findings with 
H2O2-treated enzymes were not from any residual H2O2 since it was dialysed away 
(along with any released zinc or copper). Unlike with Cu-SOD, the acceleration of 
ascorbate oxidation with the two H2O2-treated SODs was removed after adding EDTA. 
From these findings, we can say that the acceleration of ascorbate oxidation by H2O2- 
treated SODs was due to copper that is still loosely bound to the enzyme but it was 
pulled away from the active site of the enzyme by the strong chelating effect of EDTA. 
This means that oxidative damage to the SOD enzyme in sporadic ALS may lead to 
ascorbate oxidation in vivo. This mechanism represents a link between sporadic and 
familial ALS. 
The same experiment was repeated but with a different chelating agent, EGTA. 
Like EDTA, adding EGTA to the reaction media prevented the acceleration of ascorbate 
oxidation by all SOD enzyme preparations except the Zn-extracted one (Figure 5.5 
versus Figure 5.3). Also, EGTA worked better than EDTA as a chelator in preventing 
background autoxidation of ascorbate. These results are interesting in that EGTA is 
normally used as a calcium chelator and not generally recognized to inhibit metal-
catalyzed oxidations. 
Since H2O2 produced during ascorbate oxidation may contribute to the rate of 
ascorbate oxidation, the effect of adding catalase (with EGTA) to the reaction media 
before adding different SOD enzyme preparations was tested. Comparing Figures 5.6 
and 5.5, it was found that the removal of H2O2 by catalase did not decrease the rate of 
ascorbate oxidation either before or after adding the SOD enzyme preparations. This 
confirms our hypothesis that the acceleration of ascorbate oxidation was solely from the 
effect of zinc-extracted SOD enzyme on oxidation by oxygen. With native SOD, the 
presence of catalase appeared to reverse the effect of SOD from inhibiting to 
accelerating ascorbate oxidation. This is an unexpected result that might be due to the 
increased amount of oxygen from the catalase reaction or due to mass action in 
removing H2O2 product of SOD activity. 
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6.1.2 The effect of catechin and uric acid on ascorbate oxidation in presence of Cu-
SOD 
 
The second in vitro objective was to test the effect of selected flavonoids such as 
catechin or quercetin and an antioxidant, uric acid, on the rate of ascorbate oxidation in 
the presence of Cu-SOD, and to see if they might have any protective effect. Both uric 
acid and the flavonoid catechin were found to be protective against ascorbate oxidation 
by Cu-SOD by 67% and 72%, respectively. The results with quercetin were inconclusive 
due to overlapping absorbance of quercetin and ascorbate so that the extent to which the 
Cu-SOD enzyme was oxidizing ascorbate or quercetin was not clear (data not shown). 
This supports the possibility that flavonoids as antioxidants can act synergistically with 
ascorbate to decrease the oxidative damage induced by the mutant SOD in ALS, or that 
they may protect against the pro-oxidant effect of ascorbate. Since we previously found 
quercetin to be the most synergistic with ascorbate in protecting against oxidative 
damage (Bandy and Bechara, 2001), we chose to test whether dietary ascorbate with 
quercetin offer protection to FALS mice. Also, ascorbate and quercetin have been found 
to inhibit elevated ROS generation in lymphoblast cell lines from FALS patients (Said et 
al., 2000). In this study they found that L-nitroarginine, a nitric oxide synthase inhibitor 
had no effect on ROS levels, which argues against the hypothesis of Beckman et al., 
2001, of the involvement of nitric oxide in the oxidative damage that results from Zn-
deficient SOD in ALS. 
 
6.2 In vivo objectives 
 
6.2.1 Comparison between transgenic and wild type mice 
 
To investigate the role of oxidative damage in ALS pathogenesis, markers of 
oxidative stress, such as TBARS, the ratio between reduced and oxidized glutathione 
(GSH/GSSG) and total protein thiols were measured. In TBARS measurements, there 
was a 47% increase in liver TBARS in transgenic mice compared to the wild type. This 
result supports, in liver, the theory of increased oxidative stress during disease 
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progression in ALS. In the literature there is support for this theory as well. One study 
has reported higher levels of MDA in the spinal cord of FALS transgenic mice 
compared to the wild type (Hall et al., 1998), and the intensity of lipid peroxidation, 
evidenced by increased immunocytochemical staining of MDA-modified proteins, 
increased with the disease progression.  
Another marker of oxidative stress is the ratio between reduced and oxidized 
glutathione (GSH/GSSG). The role of altered glutathione metabolism in ALS is still 
unclear. The reports on GSH concentration in spinal cord or motor cortex of ALS 
patients are equivocal, and results from studies on GSH peroxidase activities in ALS are 
controversial (Schulz et al., 2000). In this study it was found that in muscle tissue, the 
ratio between reduced and oxidized-glutathione was unexpectedly 136% higher in 
control transgenic mice (CT) compared to the wild type (CW). This increase possibly 
reflected compensatory protective mechanisms in this tissue. 
In order to investigate whether tissue ascorbate is depleted in ALS mutant mice, 
and to investigate the protective role of ascorbate as an antioxidant against the oxidative 
damage that is caused by the mutant Cu/Zn SOD in ALS, total vitamin C (ascorbic acid 
and dehydroascorbic acid) and vitamin C levels were measured in brain, liver and spinal 
cord tissues. In spinal cord tissue, there was a 60% decrease in oxidized vitamin C 
(dehydroascorbic acid) in the control transgenic group (CT) compared to the wild type 
(CW). This might be against our hypothesis that the mutant SOD enzyme acts as 
ascorbate oxidase and hence increases the concentration of oxidized ascorbic acid in the 
affected area such as brain and spinal cord. However in both transgenic and wild type 
mice, the amount of oxidized-vitamin C in spinal cord was relatively small, and the 
levels of vitamin C and total vitamin C in spinal cord were slightly but insignificantly 
lower in the transgenic mice. A possible explanation for this result is that mechanisms 
for removal of dehydroascorbic acid from spinal cord were upregulated in transgenic 
mice. 
Most notable were the results in liver tissue, where the levels of oxidized-vitamin 
C (dehydroascorbic acid) in FALS transgenic mice were 29-times that of wild type mice 
(Table 5.4). This result strongly supports the hypothesis that mutant SOD can oxidize 
ascorbate which may in some way contribute to disease progression. That this increase 
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in oxidized-vitamin C is only evident in liver may be due to the liver being the site of 
ascorbate biosynthesis in animals such as mice expressing L-gulono-γ-lactone oxidase 
(Nishikimi et al., 1994). Thus, the higher level of reduced-vitamin C (43%), and much 
higher level of total vitamin C (460%) in liver of FALS transgenic mice compared to 
wild type mice might be due to induction of ascorbic acid synthesis upon an increase in 
its oxidation by the mutant SOD enzyme.  
 
6.2.2 Comparison of dietary treatments on FALS mice 
 
In order to investigate the effect of feeding ascorbate and quercetin on disease 
progression in transgenic SOD G93A mice, oxidative stress markers such as TBARS, 
and the ratio between reduced and oxidized-glutathione (GSH/GSSG), and total protein 
thiols were measured. In spinal cord tissue, there was a 98 % increase in TBARS in 
ascorbate-fed transgenic mice compared to control transgenic SOD G93A mice. This 
means feeding ascorbate did not confer protection against disease progression. Instead, it 
increased oxidative stress. This is contrary to the hypothesis that ascorbate can compete 
with mutant SOD for scavenging the superoxide anion and consequently decrease 
oxidative stress induced by the mutant enzyme. On the other hand, we considered that 
supplementation with ascorbate may worsen disease progression by increasing 
superoxide and H2O2 production catalyzed by Zn-deficient SOD. This finding is against 
what has been cited in the literature. Nagano et al., 2003 have found that feeding the 
same high dose of ascorbate as in the current studies (0.8% w/w) to FALS mice had no 
effect on disease onset, but extended the time to end-point (paralysis) of the mice by 8% 
compared to the control. I did not follow the mice to that end-point, but the current 
results suggest that feeding vitamin C does not diminish, and may increase, oxidative 
stress in the spinal cord.  
Feeding quercetin also did not decrease markers of oxidative stress in the FALS 
mice in any of the tissues. In brain tissue, there was 56%, and 58% decrease in total 
protein thiols in quercetin-fed and ascorbate + quercetin-fed transgenic mice group 
compared to control transgenic mice (Figure 5.16), suggesting that quercetin increased 
oxidative stress. These results are consistent with our observations in vitro that quercetin 
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may be co-oxidized by zinc-extracted SOD. These findings also are supported in our 
observations on the extent of disease progression in the different mice groups. From our 
observation, ascorbate + quercetin-fed transgenic mice group was the fastest group to 
develop the disease compared to other treatment groups. Another interesting finding was 
in spinal cord tissue where the level of oxidized-vitamin C was 250% higher in 
ascorbate + quercetin-fed compared to control transgenic mice. This means that feeding 
quercetin with ascorbate did not protect spinal cord against the pro-oxidant effect of 
ascorbate; instead it increased ascorbate oxidation. 
In liver, there were some results suggesting that quercetin may spare vitamin C. 
In quercetin-fed transgenic mice there was a 40% decrease in vitamin C, total vitamin C 
and oxidized-vitamin C compared to control transgenic mice (Figures 5.19 - 5.19). This 
result suggests that dietary quercetin might have led to downregulation of ascorbate 
synthesis in the liver, shown by the decreased vitamin C and total vitamin C levels. 
However dietary quercetin did not significantly decrease any of the liver indices of 
oxidative stress (Figures 5.11, 5.15, and 5.16).  
 
6.2.3 Comparisons of healthy versus diseased animals 
 
In order to see the effect of disease progression on the different parameters, the 
transgenic mice (regardless of diet) were divided into two groups: the diseased group 
(n=9) which had developed advanced signs of disease at the time of sacrificing the 
animals, and the healthy transgenic SOD G93A mice (n=11) which had no advanced 
signs of disease at the time of sacrifice. Then the different measurements were compared 
between these two groups. In muscle tissue, the levels of reduced, oxidized, and total 
glutathione were significantly higher (120%, 130%, and 130%) in diseased transgenic 
mice compared to the healthy transgenic mice. The finding that the level of oxidized 
glutathione (GSSG) in muscle tissue was 130% higher in diseased mice compared to the 
healthy ones suggests that there is increased oxidative stress in muscle tissue with 
disease progression. The increased levels of reduced and total glutathione may be due to 
compensatory upregulation of glutathione synthesis in this tissue with disease 
progression. 
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Comparing the levels of vitamin C, total vitamin C and oxidized-vitamin C 
between disease and healthy transgenic mice revealed some interesting results. In spinal 
cord tissue, the levels of vitamin C and total vitamin C were 40% and 23% higher in 
diseased transgenic mice compared to the healthy one that did not have advanced signs 
of disease at the time of sacrifice. In brain tissue the level of total vitamin C was 16% 
higher in diseased transgenic mice compared to the healthy one. This means vitamin C 
did not deplete with disease progression. Instead, it increased in the affected area (brain 
and spinal cord). This might be due to upregulation of ascorbate uptake by these tissues 
during disease progression. It should be noted that oxidized-vitamin C can be re-reduced 
by glutathione (Meister A, 1992), which may explain a lack of accumulation of oxidized 
vitamin C. We do not have glutathione measurements for spinal cord, but in brain, there 
tended to be a decrease in the GSH/GSSG ratio (Figure 5.24), which would be consistent 
with increased demand for recycling of oxidized-vitamin C. 
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7. CONCLUSIONS 
 
From in vitro experiments we conclude that zinc-deficient SOD, which might 
arise in vivo either from mutation or oxidative damage to the SOD enzyme, can catalyze 
ascorbate oxidation by molecular oxygen. This can occur with both Zn-extracted or 
H2O2-damaged SOD, but only with Zn-extracted SOD does it persist in accelerating 
ascorbate oxidation in the presence of EDTA or EGTA. This means that after zinc loss 
from the active site of the enzyme, copper becomes more exposed and thus prone to 
reduction by ascorbate and re-oxidation by oxygen. Uric acid and the flavonoid catechin 
were also found to protect ascorbate against oxidation by Cu-SOD. This supports the 
possibility that flavonoids as antioxidants can help decrease the oxidative damage 
induced by the mutant SOD in ALS. 
From in vivo study we found that ascorbate did not protect against the oxidative 
damage that is caused by the mutant Cu/Zn SOD in ALS. Instead, it increased oxidative 
stress. This was evidenced by the higher spinal cord TBARS level (93%) in ascorbate-
fed mice compared to the control FALS mice. From our study, supplementation with 
ascorbate would appear to worsen disease progression by increasing superoxide and 
H2O2 production catalyzed by Zn-deficient SOD. 
Supplementation with quercetin alone or together with ascorbate did not protect 
against the oxidative damage in FALS mice, even depleting protein thiols in brain and 
increasing the level of oxidized-vitamin C in spinal cord. So the combined treatment of 
quercetin plus ascorbate did not protect against the pro-oxidant effect of ascorbate; 
instead adding quercetin unexpectedly increased oxidative stress in ALS. 
One interesting finding is the higher level of oxidized-vitamin C in liver of FALS 
mice (29-times that of wild-type mice). This result coincided with 47% higher liver 
TBARS in FALS mice. These findings strongly support an involvement of mutant 
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SOD in oxidation of vitamin C and production of reactive oxygen species in liver. This 
effect may be amplified in liver due to compensatory upregulation of vitamin C 
biosynthesis in this organ. Feeding quercetin may be able to spare ascorbate, as 
evidenced by 40% lower levels of oxidized, reduced and total vitamin C in liver of 
quercetin-fed FALS mice. 
In summary, these results support the hypothesis that zinc-deficient and mutant 
SOD can accelerate ascorbate oxidation in vitro and in vivo. The role of ascorbate and 
quercetin as antioxidants in ALS is not supported by our in vivo results. A limitation of 
this study however was the small sample size (5 mice per group). Nevertheless, the very 
large increase in liver dehydroascorbate in FALS mice points to a substantial 
disturbance of ascorbate homeostasis. Further investigation needs to be done to 
determine the role of ascorbate or flavonoids in ALS. 
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8. FUTURE STUDIES 
 
These are some suggestions for the future studies: 
1- Consider using higher number of FALS mice (8-10 mice/group), although we 
are limited by the high price of the transgenic mice, and that the supplier could only 
supply 20 at the same age.  
2- The flavonoids and ascorbic acid could be injected intraperitoneally instead of 
feeding them. In this way we can avoid the inhibitory effect of flavonoids, especially 
quercetin, on ascorbate absorption and can achieve higher bioavailability of both 
flavonoids and ascorbate in tissues. 
3- Consider using catechin instead of quercetin as catechin showed some 
protective effect in the in vitro study and we did not get positive results in vivo with 
quercetin.  
4- Searching for a source of the mutant SOD, such as purifying it from the liver 
of FALS mice, and test the effect of the mutant SOD on ascorbate oxidation in vitro. 
5- Using red blood cells or tissue homogenates from FALS mice to test the effect 
of the mutant SOD on ascorbate oxidation in vitro. 
   By combining all these factors we could find out the effect of mutant SOD on 
ascorbate oxidation and if flavonoids could help with ascorbate in maintaining the 
antioxidant balance inside the body during the course of ALS disease. 
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